Peptide-bonded alginate gels containing radionuclides.

The alginate gel with peptide-bound radionuclides addresses the issues of non-specific binding and leakage in existing systems by stabilizing radionuclides within the gel network, enabling targeted and effective radiotherapy for proliferative diseases.

JP2024540995APending Publication Date: 2024-11-06BLUE WAVE THERAPEUTICS GMBH
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
JP2024524407
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-10-21
Filing Date
2022-10-19
Publication Date
2024-11-06

AI Technical Summary

Technical Problem

Existing radionuclide delivery systems for radiotherapy are non-biocompatible, non-biodegradable, and prone to toxic and immunogenic reactions due to radionuclide leakage and non-specific binding, leading to off-target toxicity and inefficient targeting of proliferative diseases.

Method used

Development of an alginate gel comprising peptide-bound alginate that selectively binds radionuclides through chelation, using peptides to target specific cell receptors and stabilize radionuclides within the gel network, ensuring precise delivery to affected cells.

Benefits of technology

The alginate gel effectively retains radionuclides, minimizing leakage and off-target toxicity, while providing targeted therapy for proliferative diseases by ensuring the radionuclides remain close to the desired cells, enhancing therapeutic efficacy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024540995000007
    Figure 2024540995000007
  • Figure 2024540995000008
    Figure 2024540995000008
  • Figure 2024540995000009
    Figure 2024540995000009
Patent Text Reader

Abstract

The present invention relates to an alginate-based gel for use in radiotherapy. More specifically, the present invention provides an alginate gel comprising a peptide-bonded alginate, at least one divalent cation, and at least one radionuclide cation, a method for providing at least one alginate gel particle, a composition comprising said alginate gel, said alginate gel or composition for use as a pharmaceutical, said alginate gel or composition for use in a method for treating a proliferative disease, and a kit comprising alginate and a radionuclide cation.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to an alginate gel for use in radiotherapy. More specifically, the present invention provides an alginate gel comprising a peptide-bonded alginate, at least one divalent cation, and at least one radionuclide cation, a method for providing at least one alginate gel particle, a composition comprising said alginate gel, said alginate gel or composition for use as a pharmaceutical, said alginate gel or composition for use in a method for treating a proliferative disease, and a kit comprising alginate and a radionuclide cation. [Background technology]

[0002] Alpha and beta particle emitting radionuclides have unique properties that make them attractive for use in the treatment of various diseases, such as cancer. However, delivery of the radionuclides can be difficult.

[0003] It has been previously suggested that alpha emitters can be used bound to microparticles and colloids for internal radionuclide therapy. However, many colloidal and ceramic particle and microsphere formulations represent non-biocompatible or non-biodegradable formulations, as the microspheres are toxic or cause immunogenic reactions. Because the particles cannot be easily degraded, the toxicity and immunogenic reactions typically continue for a long time after the radiation has decayed.

[0004] Successful delivery of radiation to undesirable cells depends on stable radioisotope-carrier interactions to prevent unexpected side effects caused by radioisotope leakage, as well as specific targeting of the radioisotope-carrier to undesirable cells. A problem with prior art formulations is that the radionuclide may be released from the composition, and / or the daughter nuclide formed from the radioactive decay of the initially incorporated radionuclide may not bind to the carrier. The result is undesirable off-target toxicity when the released radionuclide diffuses or is transported away from the target. Another problem with prior art formulations is that they often rely on non-specific binding to structures (e.g., bone) close to undesirable cells, or local application close to undesirable cells to achieve targeting.

[0005] Therefore, there is a need for improved drugs for radiation therapy. [Brief description of the drawings]

[0006] [Figure 1] FIG. 1 shows cation chelation by alginate. [Diagram 2] FIG. 1 shows a micrograph of alginate gel microspheres. [Diagram 3] FIG. 1 shows the results of measuring radioactivity over time from radium-223 bound to calcium cross-linked homogelling alginate microspheres. [Figure 4] FIG. 1 shows the results of measuring radioactivity over time from lead-211 bound to calcium cross-linked homogelling alginate microspheres. [Diagram 5] FIG. 1 shows the results of measuring radioactivity over time from bismuth-211 bound to calcium cross-linked homogelling alginate microspheres. [Figure 6] FIG. 1 shows the results of measuring radioactivity over time from radium-223 bound to strontium cross-linked heterogeneous gelling alginate microspheres. [Figure 7]FIG. 1 shows the results of measuring radioactivity over time from lead-211 bound to strontium cross-linked heterogeneous gelling alginate microspheres. [Figure 8] FIG. 1 shows the results of measuring radioactivity over time from bismuth-211 bound to strontium cross-linked heterogeneous gelling alginate microspheres. [Figure 9] FIG. 1 shows the results of measuring radioactivity over time from actinium-225 and the decay daughter radionuclides francium-22 and bismuth-213 bound to strontium cross-linked homogelling alginate microspheres. [Figure 10] FIG. 1 shows the results of measuring radioactivity over time from radium-223 bound to barium cross-linked heterogeneous gelling alginate microspheres. [Figure 11] FIG. 1 shows the results of measuring radioactivity over time from lead-211 bound to barium cross-linked heterogeneous gelling alginate microspheres. [Figure 12] FIG. 1 shows the results of measuring radioactivity over time from bismuth-211 bound to barium cross-linked heterogeneous gelling alginate microspheres. [Figure 13] FIG. 1 shows the results of time-dependent measurement of radioactivity from actinium-225 bound to calcium alginate microparticles and its decay daughter radionuclides francium-221 and bismuth-213 in solution. [Figure 14] FIG. 1 shows the results of measuring radioactivity over time upon addition of various amounts of actinium-225 bound to calcium alginate microparticles. [Figure 15] FIG. 1 shows the results of measuring radioactivity over time upon addition of various amounts of francium-221 bound to calcium alginate microparticles. [Figure 16] FIG. 1 shows the results of measuring radioactivity over time upon addition of various amounts of bismuth-213 bound to calcium alginate microparticles. [Figure 17] FIG. 1 shows the weight of various alginate gels over time. [Figure 18] FIG. 1 shows the average channel number versus the concentration of FITC-RGD peptide added to MDCK cells in experiments relating to binding of the peptide to cells. [Figure 19] FIG. 1 shows the change in cell number over time when various alginate gels were added. Summary of the Invention

[0007] In one aspect, the invention relates to an alginate gel according to claim 1, which comprises an alginate comprising at least one peptide having a peptide sequence for interacting with a receptor of a cell affected by a proliferative disease; Ba 2+ , Sr 2+ , Ca 2+ , Cu 2+ , Zn 2+ and combinations thereof; and Actinium-225, Actinium-228, Astatine-211, Barium-140, Bismuth-210, Bismuth-211, Bismuth-212, Bismuth-213, Calcium-45, Calcium-47, Copper-64, Francium-221, Gallium-67, Holmium-166, Indium-111, Iridium-192, Iron-59, Lead-211, Lead-212, Lead-214, Lutetium-177, Osmium-191, Osmium-193, Palladium-103, Platinum-197, Radium-223, Radium-224, Radium-225, Rhenium-186, Rhenium-188, Samarium-1 53, scandium-46, scandium-47, silver-111, strontium-85, strontium-89, tellurium-129, tellurium-132, terbium-160, terbium-161, thallium-201, thallium-206, thallium-210, thorium-227, thorium-231, thorium-234, tin-113, tungsten-185, tungsten-187, vanadium-48, ytterbium-169, yttrium-88, yttrium-90, yttrium-91, zirconium-95, and combinations thereof; and Including, The alginate chelates a divalent cation and at least one radionuclide cation; Concerning alginate gels.

[0008] Advantageously, the gel is capable of binding radionuclide cations by chelation, while the peptide sequence provides selectivity to particular cells.

[0009] In another aspect, the present invention provides a method for providing at least one alginate gel particle comprising an alginate comprising at least one peptide having a peptide sequence for interacting with a receptor of a cell affected by a proliferative disease and at least one radionuclide cation, as described in claim 6, the method comprising: i) providing a solution of alginate, the alginate comprising at least one peptide having a peptide sequence for interacting with a receptor of a cell affected by a proliferative disease; ii) adding the solution from step i) dropwise to an aqueous solution containing divalent cations, said divalent cations being Ca 2+ , Sr 2+ , and Ba 2+ forming at least one alginate gel particle; iii) contacting the alginate gel particles of step ii) with a solution containing at least one radionuclide cation; The present invention relates to a method comprising the steps of:

[0010] In another aspect, as claimed in claim 7, the present invention relates to a composition comprising the above-mentioned alginate gel together with at least one pharma- ceutically acceptable carrier, diluent and / or excipient.

[0011] In another aspect, the present invention provides a kit comprising: In a first container, at least one peptide having a peptide sequence for interacting with a receptor of a cell affected by a proliferative disease; Ba 2+ , Sr 2+ , Ca 2+ , Cu 2+ , Zn 2+ and at least one divalent cation selected from the group consisting of Alginate, including an alginate gel comprising Optionally, with a suitable solvent Including, In a second container, at least one radionuclide cation; With a suitable solvent The present invention relates to a kit comprising:

[0012] In another aspect, the present invention provides a kit comprising: In a first container, - a water-soluble alginate, The alginate comprises at least one peptide having a peptide sequence for interacting with a receptor of a cell affected by a proliferative disease, A water-soluble alginate; -Water, -Optionally with another suitable solvent Including, In a second container, - Water-insoluble particles, the particles being composed of alginate and Ba 2+ , Sr 2+ , Ca 2+ , Cu 2+ , Zn 2+ and combinations thereof; and -Water and Including, In a third container, at least one radionuclide cation, - with suitable solvent The present invention relates to a kit comprising:

[0013] In another aspect, the present invention relates to a gel or composition as described above for use as a medicament, as defined in claim 10.

[0014] In another aspect, the present invention relates to a gel or composition as described above for use in the treatment of a proliferative disease, as claimed in claim 11. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0015] Unless otherwise defined, all terms, designations and other scientific or technical terms used herein are intended to have the meaning commonly understood by those skilled in the art to which the present invention belongs. In some cases, terms having a commonly understood meaning are defined herein for clarity and / or ease of reference, and the inclusion of such definitions herein should not necessarily be interpreted as representing a substantial difference from what is commonly understood in the art.

[0016] The inventors have discovered that alginate gels, including alginate containing at least one peptide with a peptide sequence for interacting with a receptor on cells affected by a proliferative disease, can be used to stably chelate radionuclides and selectively deliver radiation to unwanted cells. The radionuclide cations can compete with the gelling ions of the alginate gel for binding to the alginate, replacing some of the original gelling ions and thereby becoming part of the gel network themselves. When the radionuclide cations are chelated by the alginate to form part of the alginate-based gel, the alginate gel can effectively and firmly hold the radionuclide in place by chelation. The peptides can provide significant selectivity. Thus, such alginate gels containing radionuclides represent promising drug candidates.

[0017] Thus, in one aspect, the present invention provides an alginate gel comprising a peptide-bound alginate, the peptide being for interacting with a receptor of a cell affected by a proliferative disease, the alginate gel being selected from the group consisting of actinium-225, actinium-228, astatine-211, barium-140, bismuth-210, bismuth-211, bismuth-212, bismuth-213, calcium-45, calcium-47, copper-64, francium-221, gallium-67, holmium-166, indium-111, iridium-192, iron-59, lead-211, lead-212, lead-214, lutetium-177, osmium-191, osmium-193, palladium-103, platinum-197, radium-223, radon-197, rhodium ... In one aspect of the present invention, the alginate gel further comprises a radionuclide cation selected from the group consisting of tungsten-224, radium-225, rhenium-186, rhenium-188, samarium-153, scandium-46, scandium-47, silver-111, strontium-85, strontium-89, tellurium-129, tellurium-132, terbium-160, terbium-161, thallium-201, thallium-206, thallium-210, thorium-227, thorium-231, thorium-234, tin-113, tungsten-185, tungsten-187, vanadium-48, ytterbium-169, yttrium-88, yttrium-90, yttrium-91, zirconium-95, and combinations thereof.

[0018] In some embodiments, the present invention provides an alginate gel comprising: an alginate comprising at least one peptide having a peptide sequence for interacting with a receptor of a cell affected by a proliferative disease; Ba 2+ , Sr 2+ , Ca 2+ , Cu 2+ , Zn 2+ and combinations thereof; and Actinium-225, Actinium-228, Astatine-211, Barium-140, Bismuth-210, Bismuth-211, Bismuth-212, Bismuth-213, Calcium-45, Calcium-47, Copper-64, Francium-221, Gallium-67, Holmium-166, Indium-111, Iridium-192, Iron-59, Lead-211, Lead-212, Lead-214, Lutetium-177, Osmium-191, Osmium-193, Palladium-103, Platinum-197, Radium-223, Radium-224, Radium-225, Rhenium-186, Rhenium-188, Samarium-1 53, scandium-46, scandium-47, silver-111, strontium-85, strontium-89, tellurium-129, tellurium-132, terbium-160, terbium-161, thallium-201, thallium-206, thallium-210, thorium-227, thorium-231, thorium-234, tin-113, tungsten-185, tungsten-187, vanadium-48, ytterbium-169, yttrium-88, yttrium-90, yttrium-91, zirconium-95, and combinations thereof; and Including, The alginate chelates a divalent cation and at least one radionuclide cation; Concerning alginate gels.

[0019] Alginate, structure I, is a structural polysaccharide found in brown algae, constituting up to 40% of the dry matter. Its main function is to provide strength and flexibility to algal tissues. Alginate is an unbranched binary copolymer of (1→4) linked β-D-mannuronic acid (M) and α-L-guluronic acid (G) residues. In the diagram of structure I below, "G" and "M" identify α-L-guluronic acid and β-D-mannuronic acid, respectively. The numbering of the carbons, as well as the type of glycosidic bond (α and β) are also shown. [ka]

[0020] The relative amounts of the two uronic acid monomers and their sequential arrangement along the polymer chain vary greatly depending on the origin of the alginate. The uronic acid residues are distributed along the polymer chain in a pattern of blocks, where homopolymer blocks of glucuronic acid (G) residues (G blocks), homopolymer blocks of mannuronic acid (M) residues (M blocks) and blocks with alternating sequences of M and G units (MG blocks) coexist. Thus, an alginate molecule cannot be described by its monomer composition alone. NMR characterization of the sequence of M and G residues in the alginate chain is required to calculate the average block length. It has also been shown by NMR spectroscopy that alginates do not have regular repeating units. The functional properties of alginate are mainly influenced by the G content, the average number of G in the G block length and the molecular weight.

[0021] Alginate is classified into the following order: Pb 2+ >Cu 2+ =Ba 2+ >Sr 2+ >Cd 2+ >Ca 2+ >Zn 2+ >Co 2+ >Ni 2+ Alginate has a strong affinity for cations that decrease with increasing pH. Alginate forms gels with most divalent and multivalent cations, although calcium is the most widely used. The cations used to form alginate gels are called "gelling ions". Most monovalent cations and divalent Mg 2+ ions do not induce gelation, but Ba 2+ and Sr 2+ Ions like Ca 2+Produces stronger alginate gels. The gelation reaction, i.e., the formation of alginate-based gels, occurs when cations participate in the interchain bonds between G-blocks in the alginate molecule, giving rise to a three-dimensional network in the form of a gel. As shown in Figure 1, cations, shown as dark spheres in Figure 1 and sometimes referred to as gelling cations, are effectively chelated by alginate through ionic interactions between the cations and lone pair electrons of hydroxyl groups and oxygen atoms in glycosidic bonds. For example, consecutive glucuronic acid residues have the ability to crosslink with cations. In particular, calcium, strontium and barium effectively crosslink alginate polymer chains forming the gel.

[0022] Gelation by calcium ions, for example, results in the instantaneous formation of a heat-stable gel that can be formed and solidified at room temperature and physiological pH. Gel strength depends on the guluronic content and the average number of G units in the G block. Furthermore, the use of alginates with increased molecular weight also increases the strength of the gel, at least up to a certain limit of molecular weight. High G content generally results in stronger, stiffer, more brittle and more porous gels. Conversely, high M content results in more elastic and weaker gels.

[0023] The present invention provides an alginate gel. The term "gel" as used herein is intended to mean a three-dimensional network organization with the ability of liquids to interpenetrate, and the structurally coherent matrix may contain a majority of liquid. The gel may contain the aforementioned liquid or may be dry. A "dry" gel may be prepared by drying a "wet" gel or may be obtained by any other method known to those skilled in the art, such as precipitation. The gel may be in various forms, including but not limited to block gels, foams, pastes, amorphous gels, and particles. When water is the solvent, the gel may be defined as a "hydrogel".

[0024] It is known from the literature that biopolymer alginate can occur as mannuronate-rich or guluronic acid-rich polymers, i.e., the compositional percentage of alginate is more than 50% mannuronic acid in mannuronate-rich alginate, while the compositional percentage is more than 50% guluronic acid in guluronic acid-rich alginate. G-rich alginate can have a higher percentage of guluronic acid residues and a series of more consecutive guluronic acid moieties, i.e., G-block size. It is further known that G-rich alginate can bind more cations than M-rich alginate, and thus form stronger polymer gel matrix. M-rich alginate has fewer binding sites and therefore forms weaker gels when crosslinked. Gels made from M-rich alginate and G-rich alginate have different strengths and also bind, e.g., chelate, different amounts of radionuclides. As known to those skilled in the art, variations in polymer chain length (degree of polymerization, DPn) or weight-average or number-average molecular weight are acceptable.

[0025] Thus, the alginate gel of the present invention can be based on M-rich alginate, G-rich alginate, or a combination thereof. In some embodiments, the alginate gel is based on G-rich alginate. In a preferred embodiment, the average number of G units in the G block of the alginate gel is greater than 1. The gel can be a hydrogel, an organogel, or a xerogel. Preferably, the gel is a hydrogel.

[0026] The alginate gel of the present invention preferably contains an alginate having a molecular weight of 500-350,000, preferably 10,000-250,000, and more preferably 25,000-150,000.

[0027] As used herein, the term "alginate gel" refers to any gel formed from an alginate salt that chelates any type of cation. Those of skill in the art are generally familiar with alginate gels, their composition, and methods of forming such gels.

[0028] The alginate gel of the present invention comprises an alginate comprising at least one peptide having a peptide sequence for interacting with a receptor of a cell affected by a proliferative disease, such as a cell adhesive peptide, such as a cell adhesion peptide. As used herein, the term "receptor" means any compound or composition capable of recognizing a specific spatial and polar configuration of a molecule, i.e., an epitopic site. The receptor is typically a cell surface receptor, such as a membrane receptor, such as a transmembrane receptor, capable of receiving, e.g., binding, at least one extracellular molecule. Advantageously, the receptor is expressed alone or overexpressed by a cell affected by a proliferative disease. The interaction of cells with biomaterials is often mediated through a cell receptor that recognizes an adhesion molecule on the material surface. Thus, the presence in an alginate gel of a peptide having a peptide sequence for interacting with a receptor of a cell affected by a proliferative disease may improve cell adaptability to the alginate gel compared to a corresponding gel that does not contain such a peptide. It is known from the art that the chemical and physical properties of alginate can be modified by binding other compounds to the alginate polymer. However, when peptides are present on the alginate polymer, it is known that the gel properties are primarily related to the G content and molecular weight of the alginate, rather than the presence and / or amount of peptide. Furthermore, it has been demonstrated that the amount of peptide does not affect alginate gelation, which is essentially the same mechanism that relies on the incorporation of radionuclide cations, at least 3.9x10 -6 From 2x10 -5 Range of moles peptide / g alginate.

[0029] The peptide sequence for interacting with a receptor of a cell affected by a proliferative disease is selected from the group of peptide sequences known to the skilled artisan to be capable of interacting with, e.g. binding to, a receptor of a cell affected by a proliferative disease, the receptor being preferably a receptor expressed on the surface of said cell.

[0030] The proliferative disease may be malignant or benign. The cell affected by the proliferative disease may be selected from the group consisting of or including tumor cells, cancer cells, cells affected by hyperplastic disease, and cells affected by neoplastic disease. In a preferred embodiment, the at least one peptide having a peptide sequence for interacting with a receptor of the cell affected by the proliferative disease is at least one peptide having a peptide sequence for interacting with a receptor of a cancer cell. As used herein, the terms "cancer cell" and "tumor cell" refer to cells that divide at an abnormally increased rate. Cancer cells include, but are not limited to, cancers such as squamous cell carcinoma, non-small cell carcinoma (e.g., non-small cell lung cancer), small cell carcinoma (e.g., small cell lung cancer), basal cell carcinoma, sweat gland carcinoma, sebaceous gland carcinoma, adenocarcinoma, papillary carcinoma, papillary adenocarcinoma, cystadenocarcinoma, medullary carcinoma, undifferentiated carcinoma, bronchogenic carcinoma, melanoma, renal cell carcinoma, hepatocellular carcinoma, cholangiocarcinoma, cholangiocarcinoma, papillary carcinoma, transitional cell carcinoma, choriocarcinoma, semonoma, embryonal carcinoma, breast cancer, gastrointestinal tract cancer, colon cancer, bladder cancer, prostate cancer, and squamous cell carcinoma of the neck and head, sarcomas such as fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteosarcoma, chord sarcoma, angiosarcoma, endothelial sarcoma, lymphangiosarcoma, synovial sarcoma, and mesothelial sarcoma, and tumors of the nervous system including glioma, glioblastoma multiforme, meningioma, medulloblastoma, schwannoma, and ependymoma. Those skilled in the art are knowledgeable about peptide sequences that can be used to interact with specific types of cells affected by proliferative diseases, particularly cancer cells.

[0031] In the present disclosure, peptides are referred to using the single-letter abbreviations of the amino acids that make up the relevant parts or the entirety of their peptide sequences. These abbreviations are familiar to those skilled in the art. In one embodiment, the peptide sequence is selected from the group comprising integrin-binding peptide sequences, LDL-binding peptide sequences, MMP-2-binding peptide sequences, IL13R2a-binding peptide sequences, VDAC1-binding peptide sequences, NBD-binding peptide sequences, cMYC-binding peptide sequences, CXCR4-binding peptide sequences, MDGI-binding peptide sequences, and combinations thereof. In a preferred embodiment, the peptide sequence is selected from the group comprising integrin-binding peptide sequences. As used herein, the term "binding" when referring to a receptor-binding peptide can be understood as being capable of interacting and / or chemically binding to said receptor due to the peptide having a peptide sequence that can interact with said receptor.

[0032] Preferably, the at least one peptide is an integrin binding peptide such as RGD, c(RGDfK), an LDL binding peptide such as TFFYGGSRGKRNNFKTEEY, an MMP-2 binding peptide such as MCMPCFTTDHQMARKCDDCCGGKGRGKCYGPQCLCR, an IL13R2a binding peptide such as ACGEMGWGWVRCGGSLCW, a VDAC1 binding peptide such as SWTWEKKLETAVNLAWTAGNSNKWTWK, an NBD binding peptide such as TALDWSWLQTE, a WP binding peptide such as WLQTE, or a WLQTE. The peptides are selected from the group including or consisting of cMYC-binding peptides such as GSGNELKRAFAALRDQI, CXCR4-binding peptides such as RACRFFC, MDGI-binding peptides such as ACGLSGLGVA, EGFR-binding peptides such as YHWYGYTPQNVI, YHWYGYTPENVI, YHWYGYTPQDVI, YHWYGYTPKNVI, YHWYGYTPQKVI, KLARLLT, cyclo(KLARLLT), and NK1-binding peptides such as substance P(RPKPQQFFGLM). In some embodiments, at least one peptide is selected from the group of RGD, TFFYGGSRGKRNNFKTEEY, MCMPCFTTDHQMARKCDDCCGGKGRGKCYGPQCLCR, ACGEMGWGWVRCGGSLCW, SWTWEKKLETAVNLAWTAGNSNKWTWK, TALDWSWLQTE, WPGSGNELKRAFAALRDQI, RACRFFC, ACGLSGLGVA, and RPKPQQFFGLM.

[0033] In some embodiments, at least one peptide is selected from Table 1 below based on target receptor and / or tumor expression. [Table 1]

[0034] The number of peptides having a peptide sequence for interacting with a receptor of a cell affected by a proliferative disease per alginate molecule can vary. In some embodiments, the alginate molecule comprises one peptide having a peptide sequence for interacting with a receptor of a cell affected by a proliferative disease. In a preferred embodiment, the alginate molecule comprises at least two peptides having a peptide sequence for interacting with a receptor of a cell affected by a proliferative disease, such as at least three, such as at least five. In some embodiments, the alginate gel of the present invention comprises at least two alginate molecules, at least one of the alginates comprising more of the aforementioned peptides than another alginate.

[0035] In some embodiments, at least one peptide is selected from the group comprising or consisting of integrin-binding peptides. Integrins are known to play a role in cancer and represent an opportunity to develop therapeutic agents capable of specifically binding to integrins.

[0036] In certain embodiments, the alginate comprises a peptide having a sequence of arginine-glycine-aspartic acid (RGD). The RGD peptide sequence has been shown to bind to integrin αvβ3. Alginate comprising a peptide containing the sequence RGD has been shown to have the ability to initiate biological interactions between alginate hydrogels and cells, and targeted binding of RGD peptides to αvβ3 has been used in tumor imaging studies. RGD-alginate, which is conveniently available commercially, can be used to specifically target integrin-expressing tumors. The gel can then be conjugated to a radionuclide to effectively target integrin-expressing tumors. The affinity and selectivity for various types of integrin receptors vary between cell types and depend on the adjacent amino acids of RGD as well as the conformation and length of the peptide. Thus, as will be appreciated by those skilled in the art, the type of optimal RGD-containing peptide sequence and RGD density may vary depending on the cells affected by the proliferative disease to be targeted.

[0037] At least one peptide may be linear. At least one peptide may be cyclic. Advantageously, certain cyclic peptides show increased affinity for cell receptors, for example enhanced binding to EGFR and integrin receptors.

[0038] At least one peptide may consist of a peptide sequence for interacting with a receptor of a cell affected by a proliferative disease. Preferably, the peptide comprises a peptide sequence for interacting with a receptor of a cell affected by a proliferative disease. In some embodiments, the peptide comprises a peptide sequence for interacting with a receptor of a cell affected by a proliferative disease and a further peptide sequence, for example a further peptide sequence between the peptide sequence for interacting with a receptor of a cell affected by a proliferative disease and the alginate. The further sequence may be, for example, a "spacer", i.e. a sequence for ensuring a desired distance between the peptide sequence for interacting with a receptor of a cell affected by a proliferative disease and the alginate, for example to allow a better interaction with the receptor. A non-limiting example of such a further sequence is a sequence comprising at least 1 to 4 glycines, such as GRGDSP, such as GGGGRGDSP.

[0039] The at least one peptide having a peptide sequence for interacting with a receptor of a cell affected by a proliferative disease may be directly linked to the alginate, such as via a covalent bond, e.g., via an amide bond, or the at least one peptide having a peptide sequence for interacting with a receptor of a cell affected by a proliferative disease may be linked to the alginate via a linking group.

[0040] Methods for linking peptides to alginate directly or via linking groups are well known in the art and may use standard chemistries such as aqueous carbodiimide coupling. Suitable linking groups may be readily determined by those skilled in the art. For example, a variety of linking groups are known in the field of antibody-drug conjugates. Non-limiting examples of linking groups include poly(ethylene glycol) (PEG) and 2-(maleimidomethyl)-1,3-dioxane (MD). For purposes of the present invention, alginate may be prepared by conjugating the relevant peptide to alginate or may be commercially obtained as peptide-linked alginate. For example, peptide-linked alginate RGD-alginate is commercially available and sold under the trade name NOVATACH-4GRGDSP.

[0041] In some embodiments, the alginate gel of the present invention further comprises a peptide-free alginate, e.g., an unsubstituted alginate, having a peptide sequence for interacting with a receptor of a cell affected by a proliferative disease.

[0042] The alginate and at least one peptide may be obtained by any method known to the skilled artisan, e.g. commercially obtained, synthesized using any synthesis protocol available to the skilled artisan, e.g. enzymatically, synthetically and / or chemically produced.

[0043] The alginate gel of the present invention further comprises at least one divalent cation. The divalent cation is selected such that the alginate and the at least one divalent cation together form an alginate gel. The amount of cation required for gel formation is well known to those skilled in the art and can be determined based on factors such as the desired gel strength, the type of alginate used (G-rich or M-rich), and the isotonicity of the gelling solution. Concentrations of 50-150 mM are often used. The divalent cation is preferably Ba. 2+ , Sr 2+ , Ca 2+ , Cu 2+ , Zn 2+and combinations thereof, more preferably the divalent cation is selected from the group consisting of Ba 2+ , Sr 2+ , Ca 2+ and combinations thereof.

[0044] Those skilled in the art know how to provide alginate gel in various forms.Alginate comprising at least one peptide and at least one divalent cation can be gelled, for example, by the diffusion method of dropping said alginate into the solution of said cation (external gelling), by in situ gelling using the salt of said cation that is insoluble in water (internal gelling), or by gelling on cooling, said alginate and said cation are present in a solution at high temperature, and alginate gel is formed when the solution is cooled.

[0045] The alginate gel of the present invention further comprises at least one radionuclide cation. As used herein, the term "radionuclide", which may also be called a radionuclide, radioisotope or radioisotope, is an atom that has excess nuclear energy, making it unstable. This excess energy can be used in one of three ways: emitted from the nucleus as a gamma ray, transferred to one of its electrons and emitting it as a conversion electron, or used to create and emit a new particle (alpha particle or beta particle) from the nucleus. During these processes, the radionuclide is said to undergo radioactive decay. The resulting nuclide is called a daughter or progeny nuclide.

[0046] Preferably, the at least one radionuclide is selected from the group consisting of actinium-225, actinium-228, astatine-211, barium-140, bismuth-210, bismuth-211, bismuth-212, bismuth-213, calcium-45, calcium-47, copper-64, francium-221, gallium-67, holmium-166, indium-111, iridium-192, iron-59, lead-211, lead-212, lead-214, lutetium-177, osmium-191, osmium-193, palladium-103, platinum-197, radium-223, radium-224, radium-225, rhenium-186, rhenium-197, rhenium-227, rhenium-229, rhenium-230, rhenium-232, rhenium-234, rhenium-236, rhenium-238, rhenium-239, rhenium-240, rhenium-241, rhenium-242, rhenium-243, rhenium-244, rhenium-245, rhenium-246, rhenium-247, rhenium-248, rhenium-249, rhenium-249, rhenium-249, rhenium-240, rhenium-241, rhenium-242, rhenium-243, rhenium-244, rhenium-245, rhenium-245, rhenium-246, rhenium-247, rhen In one embodiment, the metal is selected from the group including or consisting of vanadium-188, samarium-153, scandium-46, scandium-47, silver-111, strontium-85, strontium-89, tellurium-129, tellurium-132, terbium-160, terbium-161, thallium-201, thallium-206, thallium-210, thorium-227, thorium-231, thorium-234, tin-113, tungsten-185, tungsten-187, vanadium-48, ytterbium-169, yttrium-88, yttrium-90, yttrium-91, zirconium-95, and combinations thereof. More preferably, the at least one radionuclide is selected from actinium-225, actinium-228, bismuth-210, bismuth-211, bismuth-212, lead-211, lead-212, lead-214, radium-223, radium-224, radium-225, strontium-85, strontium-89, thorium-227, thorium-231, thorium-234, yttrium-88, yttrium-90, yttrium-91, and combinations thereof.

[0047] In some embodiments, the radionuclide is selected from radium-223 and actinium-225.

[0048] In some embodiments, the radionuclide is radium-223. Advantageously, the alginate gels of the present invention can also bind the daughter decay nuclides of radium-223, namely polonium-215, lead-211, bismuth-211, thallium-207, and lead-207.

[0049] In another embodiment, the radionuclide is actinium-225. As well as radium-223, the alginate gels of the invention advantageously also bind the daughter decay nuclides of actinium-225, namely francium-221, and bismuth-213, as well as polonium-213, thallium-209, and lead-209.

[0050] As mentioned above, alginate-based gels are formed by the chelation of cations by alginate through ionic interactions between the cations of hydroxyl groups and oxygen atoms in glycosidic bonds and lone pair electrons. Radionuclide cations can compete for binding to alginate, for example by replacing some of the original cross-linked cations, thereby becoming part of the gel network itself. Thus, the radionuclide cations can become part of the three-dimensional network that is the gel. When radionuclide cations are chelated by alginate to form part of an alginate-based gel, the radionuclide is effectively and firmly held in place within the alginate gel by the chelating effect of the radionuclide, but the alginate structure is flexible enough to absorb the recoil energy of alpha particle emission, thereby effectively holding the newly formed daughter decay nuclides.

[0051] In a preferred embodiment, the gel is a heterogeneous gel. As shown in Examples 3-7, radionuclides are not efficiently released from such alginate gels.

[0052] This mode of holding active drugs, i.e. radionuclides, contrasts with the frequently used method of encapsulating drugs in alginate hydrogels. In such hydrogels, the cross-linked alginate polymer molecules actually hold water in place, and the space occupied by the water between the cross-linked polymer chains acts as a pore in which the drug can be encapsulated. However, while alginate gels effectively hold molecules with a molecular weight of more than about 50,000, molecules with lower molecular weights diffuse at a rate proportional to their charge and molecular weight. The alginate gels of the present invention are based on the principle of chelation and may allow the incorporation of active drugs that is significantly more stable than encapsulation in pores as described in the art.

[0053] According to the invention, the gel may comprise at least one radionuclide cation having an oxidation state of 2+ (divalent cation), an oxidation state of 3+ (trivalent cation), or an oxidation state of 4+ (tetravalent cation). In some embodiments, the at least one radionuclide cation is at least one divalent radionuclide cation. Since the cross-linking cations of alginate-based gels are typically divalent cations, it can be expected that divalent radionuclide cations will be relatively easy to substitute for these cations. Surprisingly, the inventors have found that the alginate gels of the invention contain Ca as the cross-linking cation. 2+ , B.A. 2+ and / or Sr 2+ It has been found that when the gel contains 1,000,000 uranium, the gel can also bind the radionuclides lutetium-177 (an element having an oxidation state of 3+) and thorium-227 (an element having an oxidation state of 4+). The gel can also bind daughter decay nuclides of thorium-227. As shown in Example 6, about 30% of the available thorium-227 is bound to the alginate gel, while 100% of the available radium, lead and bismuth nuclides are bound to the alginate gel. Thus, the disclosed alginate gel can be used for the purification of thorium-227 by removal of its daughter decay nuclides, including radium, lead or bismuth.

[0054] Alpha particles, while having very high energy, travel only a very short distance, usually less than 100 μm. If at least one radionuclide cation is or contains an alpha emitter, a significant number of alpha particles may be lost if the radionuclide cation is located too far into the gel, rather than near the surface of the gel. Therefore, if at least one radionuclide cation is or contains at least one α emitter, the at least one radionuclide cation should be located less than 100 μm below the surface of the gel, preferably less than 50 μm below the surface of the gel, more preferably less than 10 μm below the surface of the gel. Such an arrangement of the radionuclide cation can be obtained by introducing at least one radionuclide cation after gelation, i.e. by applying the radionuclide cation to the gel, rather than forming the gel first and then introducing the radionuclide cation during gelation. Thus, radiolabeling of the alginate gel of the present invention can be advantageously carried out by homogeneously mixing a solution or suspension of radionuclide cations with a suspension of the gel, such as in particulate form, and then separating the remaining unbound radionuclide cations from the labeled particles, such as by centrifugation or column purification.

[0055] The alginate gels of the present invention are particularly suitable for delivering radioactive decay in vivo. The gels are biocompatible and biodegradable and may provide a higher level of physical flexibility and compressibility than those found in formulations containing solid minerals, such as those described by ceramics and glasses. Furthermore, the presence of peptides to interact with tumor cells may contribute to highly selective radiotherapy, ensuring that the alginate gel, and therefore the radionuclide, is physically close to the tumor cells. Depending on the form of the alginate gel (e.g., particles vs. block gels) and the type of administration to the subject (e.g., intravenous administration vs. direct injection at the tumor site), the peptides may act as "targeting units" mirroring, for example, the targeting units used in ADC (antibody drug conjugate) technology, and / or may function to ensure that the alginate gel remains in place over time. The physical form of the gel may also contribute to the latter. Furthermore, stable chelation of the radionuclide and its progeny to the gel ensures efficient radiotherapy with minimal leakage of radioactivity.

[0056] In some embodiments, the alginate gel of the present invention is in the form of a block gel. In other embodiments, the gel is in the form of a foam, a paste, or an amorphous gel. In yet other embodiments, the gel is in the form of particles.

[0057] In a preferred embodiment, the alginate gel of the present invention is in the form of at least one particle, such as at least one nanoparticle, such as at least one microparticle, such as at least one rod, such as at least one fiber, such as at least one spray-dried particle and / or freeze-dried particle, preferably at least one microparticle.Advantageously, the particle can be easily incorporated into an injectable composition.Furthermore, the particle is dry and therefore can be easily stored.

[0058] Thus, in these embodiments, the invention provides alginate gel particles comprising: an alginate comprising at least one peptide having a peptide sequence for interacting with a receptor of a cell affected by a proliferative disease; Ba 2+ , Sr 2+ , Ca 2+ , Cu 2+ , Zn 2+ and combinations thereof; and Actinium-225, Actinium-228, Astatine-211, Barium-140, Bismuth-210, Bismuth-211, Bismuth-212, Bismuth-213, Calcium-45, Calcium-47, Copper-64, Francium-221, Gallium-67, Holmium-166, Indium-111, Iridium-192, Iron-59, Lead-211, Lead-212, Lead-214, Lutetium-177, Osmium-191, Osmium-193, Palladium-103, Platinum-197, 0, Radium-223, Radium-224, Radium-225, Rhenium-186, Rhenium-188, Samarium- at least one radionuclide cation selected from the group consisting of: silver-153, scandium-46, scandium-47, silver-111, strontium-85, strontium-89, tellurium-129, tellurium-132, terbium-160, terbium-161, thallium-201, thallium-206, thallium-210, thorium-227, thorium-231, thorium-234, tin-113, tungsten-185, tungsten-187, vanadium-48, ytterbium-169, yttrium-88, yttrium-90, yttrium-91, zirconium-95, and combinations thereof; Including, The alginate chelates a divalent cation and at least one radionuclide cation; This results in alginate gel particles.

[0059] The embodiments and features described in the context of alginate gel apply equally to alginate gel particles.

[0060] As used herein, the term "particle" refers to a mass of material, such as a sphere, such as a bead. In some embodiments, the particle is a nanoparticle or a microparticle, preferably a nanoparticle. As used herein, the term "nanoparticle" refers to any particle having a diameter less than 1000 nm, e.g., between 1 and 1000 nm. Similarly, the term "nanoparticle" refers to a plurality of particles having an average diameter between about 1 and 1000 nm. The term "microparticle" refers to any particle having a diameter less than 1000 μm, e.g., between 1 and 1000 μm. Similarly, the term "microparticle" refers to a plurality of particles having an average diameter between about 1 and 1000 μm.

[0061] Advantageously, the alginate gel particles have a size of 10-100000 nm, such as 50-10000 nm, for example 50000-80000 nm, preferably 10-40000 nm. References to the "size" of a particle are references to the length of the particle's largest linear dimension. For example, the size of a spherical particle is its diameter. Size can refer, for example, to the hydrodynamic radius of the particle as characterized by dynamic light scattering.

[0062] In some embodiments, the alginate gel particles contain only one of the aforementioned peptides. In other embodiments, the particles contain two or more of the aforementioned peptides, such as five, such as ten. The number of the aforementioned peptides can be selected based on the size of the particle. The peptides can be the same or different from each other. The mass ratio of peptide to particle can depend on the molecular weight of the peptide and the diameter of the particle.

[0063] In some embodiments, the alginate gel particles contain one radionuclide cation, while in other embodiments, the particles contain one or more of the following radionuclide cations: actinium-225, actinium-228, astatine-211, barium-140, bismuth-210, bismuth-211, bismuth-212, bismuth-213, calcium-45, calcium-47, copper-64, francium-221, gallium-67, holmium-166, indium-111, iridium-192, iron-59, lead-211, lead-212, lead-214, lutetium-177, osmium-177, selenium-178, selenium-179, selenium-180, selenium-181, selenium-182, selenium-183, selenium-184, selenium-185, selenium-186, selenium-187, selenium-188, selenium-189 ... Zn-191, Osmium-193, Palladium-103, Platinum-197, Radium-223, Radium-224, Radium-225, Rhenium-186, Rhenium-188, Samarium-153, Scandium-46, Scandium-47, Silver-111, Strontium-85, Strontium-89, Tellurium-129, Tellurium-132, Terbium-160, Terbium-161, Thallium-201, Thallium-206, Thallium-210, Thorium and preferably comprises a plurality of radionuclide cations, e.g., two, e.g., three, e.g., five, independently selected from the group including or consisting of: tungsten-227, thorium-231, thorium-234, tin-113, tungsten-185, tungsten-187, vanadium-48, ytterbium-169, yttrium-88, yttrium-90, yttrium-91, zirconium-95, and combinations thereof. In particular, the cations are independently selected from actinium-225, actinium-228, bismuth-210, bismuth-211, bismuth-212, lead-211, lead-212, lead-214, radium-223, radium-224, radium-225, strontium-85, strontium-89, thorium-227, thorium-231, thorium-234, yttrium-88, yttrium-90, yttrium-91, and combinations thereof. It should be noted that in all embodiments, perfect control of the number of radionuclide cations per particle cannot be expected. During the radiolabeling process, in which the particles are contacted with a solution containing radionuclide cations, a statistical distribution of radionuclide cations per particle occurs.

[0064] It has been shown that solutions of alginate-based gels are strongly dependent on the preparation method. When gel particles are formed by the diffusion of gelling ions into a droplet of alginate solution, a non-uniform distribution of the polymer in the particle is obtained. This observation can be explained by the difference in the diffusion rate of the gelling ions into the particle relative to the diffusion rate of the alginate molecules towards the gelling zone. Calcium from the external solution diffuses into the alginate particle. In the absence of non-gelling ions (e.g. sodium, e.g. sodium chloride), the alginate molecules within the gelling particle migrate to the outer edge region of the particle. This results in localized regions of higher alginate concentration than in the center of the gel particle. This type of gelation is called "non-uniform" and the resulting gel is called a "heterogeneous gel". However, when non-gelling ions are present, the non-gelling ions compete with the gelling ions for binding to the alginate. The non-gelling ions do not induce gelation, but they retard the cross-linking action of the gelling ions. In this case, the gel forms with an essentially uniform alginate concentration throughout the alginate particle, called "uniform" gelation. The resulting gel is called a "homogeneous gel." In both cases, the gelation process is almost instantaneous.

[0065] More uniform particles may be mechanically stronger and have higher porosity than more non-uniform particles. For example, the addition of sodium chloride together with calcium chloride results in the formation of more uniform particles. Maximum uniformity is reached with high molecular weight alginates gelled at high concentrations of both gelling and non-gelling ions. Thus, while Example 2 shows that uniform alginate gel particles in the form of microspheres can be coated with radionuclide cations, preferred formulations may take advantage of non-uniform gelation to increase the alginate concentration within the outer portion of the alginate gel particle. The higher alginate concentration along the outer portion of the gel particle provides strength to the particle as well as more binding sites for, for example, radionuclide cations.

[0066] Thus, in a preferred embodiment, the alginate gel particles are heterogeneous gel particles, while in other embodiments, the alginate gel particles are homogeneous gel particles.

[0067] In some embodiments, the alginate gel particles are coated with polycations, such as to give the gel additional strength if necessary and / or to change the surface charge of the alginate gel from negative to positive. An example of a suitable polycation AON is poly-L-lysine. Alternatively, the alginate gel may be coated with the biopolymer chitosan, for example to change the surface charge to positive. The positive surface charge may be useful, for example, to bind anionic radionuclides.

[0068] In another aspect, the present invention provides a method for providing at least one alginate gel particle comprising an alginate comprising at least one peptide having a peptide sequence for interacting with a receptor of a cell affected by a proliferative disease and at least one radionuclide cation, the method comprising: i) providing an aqueous solution of an alginate, the alginate comprising at least one peptide having a peptide sequence for interacting with a receptor of a cell affected by a proliferative disease; ii) adding the solution from step i) dropwise to an aqueous solution containing divalent cations, said divalent cations being Ca 2+ , Sr 2+ , B.A. 2+ , Cu 2+ , and Zn 2+ forming at least one alginate gel particle; iii) contacting the alginate gel particles of step ii) with a solution containing at least one radionuclide cation; The present invention provides a method comprising:

[0069] The embodiments and features described above in the context of gels, and in particular gel particles, also apply to the method of providing gel particles.

[0070] This method is particularly suitable for providing microparticles. Advantageously, the method provides gel particles in which at least one radionuclide cation is contained near the surface of the particle, rather than randomly distributed throughout the particle.

[0071] The concentration of alginate in the solution of step i), corrected for the dry matter content, is preferably between 0.2 and 15% (wt / v), more preferably between 0.7 and 5% (wt / v), even more preferably between 1.5 and 2% (wt / v).

[0072] The aqueous solution containing divalent cations in step ii) preferably has a total concentration of said cations of 10-200 mM, more preferably 50-250 mM, for example 50-100 mM. The divalent cation should be a cation that induces gelation and is non-toxic or has acceptable toxicity in humans. In a preferred embodiment, the divalent cation in step ii) is Ca 2+ , Sr 2+ and Ba 2+ is selected from the group comprising or consisting of:

[0073] The solution of step i) is dripped into the aqueous solution containing divalent cations of step ii). The purpose of the dripping may be to form particles that are more or less spherical. In such cases, the dripping may be advantageously performed using an electrostatic bead generator that allows control of the size and size distribution of the particles. However, the particles may alternatively be formed by other means, such as manual or gravity droplet formation, coaxial airflow, and other techniques known to those skilled in the art. Several techniques are known in the art for producing alginate microparticles and nanoparticles. Another method involves direct spray drying of droplets composed of aqueous sodium alginate or peptide-linked alginate and aqueous calcium chloride. Other techniques, such as oil-in-water emulsions and complexation reactions, can be found in the literature. The choice of gelation method or device does not detract from the usefulness of the present invention.

[0074] It is also possible to bind the radionuclide to non-gelling solid particles of alginate.

[0075] For reference, further examples of procedures for preparing alginate gels suitable for human use can be found, for example, in ASTM Guideline F2315.

[0076] An advantage of the disclosed method is that at least one gel particle resulting from step ii) can be preformed and / or stored, and step iii) can be performed later. For example, the gel particles of step ii) can be stored, for example, in the solution of step ii) until needed. Alternatively, the gel particles of step ii) can be subjected to a spray drying or freeze drying process. Sterile alginate microspheres stored in water or NaCl solution have been shown to be stable for several years, especially when small amounts of calcium are present in the solution. Example 9 further illustrates the stability of alginate gel particles.

[0077] In some embodiments, step iii) is carried out in a buffer solution to maintain a pH between 3 and 8. The use of such a buffer may contribute to maintaining the structural integrity of the gel particles. The duration of step iii) is typically between 20 and 180 minutes, for example between 30 and 120 minutes. When using lyophilized gel particles, the volume of the radionuclide solution should be adjusted to allow rehydration of the particles, as known to those skilled in the art.

[0078] The above disclosed method utilizes the concept of external gelation. The inventors have found that for the preparation of gel particles of the invention, the disclosed method is more advantageous compared to carrying out gelation with radionuclide cations co-mixed with the cations of step ii). The latter results in the incorporation of the radionuclide cations within the gel particles, and not near the surface as in the claimed method. As mentioned above, alpha particles, while having very high energy, travel only very short distances, typically less than 100 μm. Thus, the incorporation of alpha particles emitting radionuclide cations within particles having a size of, for example, >100 μm, results in the loss of a significant number of alpha particles due to the absorption of energy within the particle itself. The method of the invention is therefore particularly useful when preparing particles containing alpha emitters.

[0079] The alginate gel particles of the present invention can be made by either homogeneous or heterogeneous gelation procedures, i.e., for homogeneous gelation, using an alginate solution and a gelling ion solution that contain a certain amount of non-gelling ions, such as NaCl, typically at a concentration of up to 0.9%, or without the addition of salts to create isotonicity. The gelling solution can be made isotonic without NaCl by using mannitol. Thus, in some embodiments, the aqueous solution containing divalent cations in step ii) further contains NaCl, e.g., for homogeneous gelation. In other embodiments, when heterogeneous gelation is desired, the aforementioned solution does not contain a substantial amount of NaCl.

[0080] Advantageously, the method may be performed aseptically by using a sterile alginate solution, a sterile cationic gelling solution, and the sterile equipment used to generate the particles may be sterilized by suitable means. For example, sterile alginate gel microspheres can be produced by dissolving sterile lyophilized sodium alginate in sterile water or other suitable diluent. Equipment for the production of microspheres, such as the NISCO VAR1 electrostatic bead generator, can be sterilized by autoclaving and ethanol disinfection. The gelling bath solution can be sterilized by filter sterilization. The entire production of alginate gel microspheres can be performed by placing the equipment on a laminar air flow (LAF) sterile bench.

[0081] Additionally, the introduction of radionuclide cations into preformed sterile alginate gel microspheres can be accomplished using a sterile solution of the appropriate radionuclide cation. After incubation to coat the gel microspheres, washing can be accomplished using a sterile solution. The sterile radionuclide-coated alginate gel microspheres can be stored in a sterile container.

[0082] The alginate gel disclosed herein can be present as an active ingredient in a desired dosage unit formulation, such as a pharma- ceutically acceptable composition containing a conventional pharma- ceutically acceptable carrier. As used herein, the term "pharma-ceutically acceptable" means that the compound must be physiologically acceptable to the recipient and, when part of a composition, must be compatible with other components of the composition. The term "composition" refers to a mixture of one or more compounds according to the present invention and one or more additional chemical components in any formulation.

[0083] Thus, in another aspect, the present invention provides a method for producing a method for treating a pulmonary arthritis, comprising: 1. An alginate gel comprising: an alginate comprising at least one peptide having a peptide sequence for interacting with a receptor of a cell affected by a proliferative disease; Ba 2+ , Sr 2+ , Ca 2+ , Cu 2+ , Zn 2+ and combinations thereof; and Actinium-225, Actinium-228, Astatine-211, Barium-140, Bismuth-210, Bismuth-211, Bismuth-212, Bismuth-213, Calcium-45, Calcium-47, Copper-64, Francium-221, Gallium-67, Holmium-166, Indium-111, Iridium-192, Iron-59, Lead-211, Lead-212, Lead-214, Lutetium-177, Osmium-191, Osmium-193, Palladium-103, Platinum-197, Radium-223, Radium-224, Radium-225, Rhenium-186, Rhenium-188, Samarium-1 53, scandium-46, scandium-47, silver-111, strontium-85, strontium-89, tellurium-129, tellurium-132, terbium-160, terbium-161, thallium-201, thallium-206, thallium-210, thorium-227, thorium-231, thorium-234, tin-113, tungsten-185, tungsten-187, vanadium-48, ytterbium-169, yttrium-88, yttrium-90, yttrium-91, zirconium-95, and combinations thereof; and Including, The alginate, together with at least one pharma- ceutically acceptable carrier, diluent, and / or excipient, chelates a divalent cation and at least one radionuclide cation; The present invention relates to a composition comprising an alginate gel.

[0084] In a preferred embodiment, the gel is in the form of particles, so that the present invention provides an alginate comprising at least one peptide having a peptide sequence for interacting with a receptor of a cell affected by a proliferative disease; Ba 2+ , Sr2+ , Ca 2+ , Cu 2+ , Zn 2+ and combinations thereof; and Actinium-225, Actinium-228, Astatine-211, Barium-140, Bismuth-210, Bismuth-211, Bismuth-212, Bismuth-213, Calcium-45, Calcium-47, Copper-64, Francium-221, Gallium-67, Holmium-166, Indium-111, Iridium-192, Iron-59, Lead-211, Lead-212, Lead-214, Lutetium-177, Osmium-191, Osmium-193, Palladium-103, Platinum-197, Radium-223, Radium-224, Radium-225, Rhenium-186, Rhenium-188, Samarium-1 53, scandium-46, scandium-47, silver-111, strontium-85, strontium-89, tellurium-129, tellurium-132, terbium-160, terbium-161, thallium-201, thallium-206, thallium-210, thorium-227, thorium-231, thorium-234, tin-113, tungsten-185, tungsten-187, vanadium-48, ytterbium-169, yttrium-88, yttrium-90, yttrium-91, zirconium-95, and combinations thereof; and Including, The alginate, together with at least one pharma- ceutically acceptable carrier, diluent, and / or excipient, chelates a divalent cation and at least one radionuclide cation; Alginate gel Alginate gel particles comprising The present invention relates to a composition comprising:

[0085] The embodiments and features described above in the context of gels, and in particular gel particles, also apply to the compositions of the present invention.

[0086] The composition may be considered to be a pharmaceutical composition since it comprises an active agent combined with at least one pharma- ceutically acceptable carrier, diluent, and / or excipient, i.e., a gel, making the composition particularly suitable for therapeutic use.

[0087] The composition preferably comprises a multiplicity of alginate gel particles of the invention. The particles may be the same or different, i.e., the same or different with respect to the type and number of radionuclide cations and / or peptides. In some embodiments, the composition is a particle suspension comprising monodisperse or polydisperse particles labeled with radionuclide cations.

[0088] The composition may further comprise one or more of any conventional pharma- ceutically acceptable excipients and / or carriers, such as solvents, fillers, diluents, binders, lubricants, glidants, viscosity modifiers, surfactants, dispersants, disintegrants, emulsifiers, wetting agents, suspending agents, thickening agents, buffers, pH adjusters, absorption retarders, stabilizers, antioxidants, preservatives, antimicrobial agents, antibacterial agents, antifungal agents, chelating agents, adjuvants, sweeteners, flavoring agents, and coloring agents. The compositions may be formulated using conventional formulation techniques known in the art, such as conventional mixing, dissolving, suspending, granulating, levigating, emulsifying, encapsulating, or encapsulating.

[0089] In some embodiments, the composition is formulated for a particular method of administration to a subject.

[0090] The amount of gel according to the invention present in the composition may vary. In some embodiments, the amount of gel according to the invention present in the composition is 0.1-50% by weight, such as 1-30%, for example 50-20%. In other embodiments, the amount of gel according to the invention present in the composition is 30-70% by weight, such as 40-60%. In yet other embodiments, the amount of gel according to the invention present in the composition is 50-100% by weight, such as 50-70%, for example 50-80%, for example 60-98%, for example 70-95%.

[0091] The composition may also include alginate gels, e.g., alginate gel particles, that do not contain radionuclide cations. Such alginate gels may be the same as the alginate gels of the invention, except for the absence of radionuclide cations, or may be different. The ratio of alginate gels containing radionuclide cations to alginate gels without radionuclide cations may vary. In a preferred embodiment, at least 90% of the alginate gel contains radionuclide cations. The activity per mg of gel may range, e.g., from 0.1 kBq / mg to 100 kBq / mg, depending, e.g., on the choice of radionuclide.

[0092] Furthermore, the composition is substantially free of contaminants or impurities. In some embodiments, the level of contaminants or impurities other than residual solvent in the composition is less than about 5% by weight based on the combined weight of the gel according to the present invention and other intended components. In certain embodiments, the level of contaminants or impurities other than residual solvent in the composition is less than about 2% or 1% by weight based on the combined weight of the gel according to the present invention and other intended components.

[0093] In certain embodiments, the gel or composition according to the present invention is sterile. The gel may be prepared aseptically as outlined above. Sterilization may be achieved by any suitable method, including but not limited to applying heat, chemicals, irradiation, high pressure, filtration, or a combination thereof.

[0094] In another aspect, the present invention provides a kit comprising: In a first container, at least one peptide having a peptide sequence for interacting with a receptor of a cell affected by a proliferative disease; Ba 2+ , Sr 2+ , Ca 2+ , Cu 2+ , Zn 2+ and at least one divalent cation selected from the group consisting of and an alginate comprising Optionally, with a suitable solvent An alginate gel comprising Including, In a second container, at least one radionuclide cation; With a suitable solvent The present invention relates to a kit comprising:

[0095] In some embodiments, the gel is in the form of gel particles. In some embodiments, all contents of the first and second containers are sterile. In some embodiments, the solvent is pharma- ceutically acceptable.

[0096] The concentration of the contents of the first and second containers can be selected based on the desired level of radiolabel per unit of, for example, gel particle. The concentration of the components of the first and second containers can be selected based on the knowledge of one of skill in the art of pharma- ceutically acceptable compositions. In some embodiments, the gel is lyophilized and the first container does not contain a solvent.

[0097] One skilled in the art will appreciate that the first and / or second container may further comprise additional components, such as at least one carrier, diluent, and / or excipient.

[0098] Internal gelation can be achieved by limiting the amount of gelling ions available for complexing with the alginate, for example by mixing the alginate solution with slowly hydrolyzing substances such as CaCO3, which has low solubility at neutral pH but higher solubility at lower pH, and glucono-δ-lactone (GDL). As the GDL hydrolyzes and the pH drops, the Ca salts dissolve and Ca 2+ions become available for gelation. Another method for making alginate gels by internal gelation is by mixing the alginate solution with a mixture of fast and / or slow dissolving gelling ion salts, such as CaCl2 and CaSO4. Internal gelation can also be performed by encapsulating gelling ions in liposomes and mixing the liposomes with the alginate solution. The liposomes can then be destabilized, i.e. by heat activation, and the subsequent release of the gelling ions causes gelation.

[0099] Delayed gelling systems, such as those disclosed in WO2006044342 and WO2009032158, are useful methods of making alginate-based gels by internal gelling. The composition is simple and does not require additional additives. The only substituents required are soluble and insoluble alginates, such as sodium alginate and calcium alginate. The saturated calcium alginate donates calcium ions to the dissolved sodium alginate, so that the system gels after a controllable time. The delayed gelling system facilitates the production of nearly uniform gels at a controlled rate without the need for pH changes or the addition of inorganic salts, so that the system offers an alternative to alginate gel production by diffusion / dialysis or by the use of a combination of calcium salts and acidic agents. Delayed gelling alginate systems have been used as tissue bulking agents in cardiac regeneration, for example, of the left ventricle after myocardial infarction.

[0100] The incorporation of one or more radionuclide cations into the delayed gelling alginate system as disclosed above represents a useful tool for internal radiotherapy, where the alginate contains at least one peptide with a peptide sequence for interacting with a receptor of cells affected by a proliferative disease, allowing direct injection into the tumor or tumor resection site. The delayed gelling reaction allows sufficient time to inject or inject the gel solution before the onset of gelling. The gelling occurs in situ, resulting in a radioactive gel at the desired site.

[0101] Thus, in another aspect, the present invention provides a kit comprising: In a first container, A water-soluble alginate comprising: The alginate comprises at least one peptide having a peptide sequence for interacting with a receptor of a cell affected by a proliferative disease, A water-soluble alginate; Water, Optionally, with another suitable solvent Including, In a second container, A water-insoluble particle, the particle being composed of an alginate and Ba. 2+ , Sr 2+ , Ca 2+ , Cu 2+ , Zn 2+ and at least one divalent cation selected from the group consisting of: Water and Including, In a third container, at least one radionuclide cation; With a suitable solvent The present invention relates to a kit comprising:

[0102] The soluble alginate may be selected from sodium alginate, magnesium alginate and / or potassium alginate, the alginate having a molecular weight of 500-350,000, preferably 10,000-250,000, more preferably 25,000-150,000.

[0103] At the time of use, the contents of the third container can be mixed with the contents of the second container and the mixture added to the contents of the first container to form a delayed gelling system for forming a radioactive gel.

[0104] The concentrations of the contents of the first, second, and third containers can be selected based on, for example, the desired level of radiolabel per unit of gel. The concentrations of the components of the first, second, and third containers can be selected based on the knowledge of one of skill in the art regarding pharma- ceutically acceptable compositions.

[0105] One skilled in the art will appreciate that the first, second, and / or third container may further comprise additional ingredients, such as at least one carrier, diluent, and / or excipient.

[0106] In another aspect, the present invention provides a method for producing a composition comprising: For use as a medicine, 1. An alginate gel comprising: an alginate comprising at least one peptide having a peptide sequence for interacting with a receptor of a cell affected by a proliferative disease; Ba 2+ , Sr 2+ , Ca 2+ , Cu 2+ , Zn 2+ and combinations thereof; and Actinium-225, Actinium-228, Astatine-211, Barium-140, Bismuth-210, Bismuth-211, Bismuth-212, Bismuth-213, Calcium-45, Calcium-47, Copper-64, Francium-221, Gallium-67, Holmium-166, Indium-111, Iridium-192, Iron-59, Lead-211, Lead-212, Lead-214, Lutetium-177, Osmium-191, Osmium-193, Palladium-103, Platinum-197, Radium-223, Radium-224, Radium-225, Rhenium-186, Rhenium-188, Samarium at least one radionuclide cation selected from the group consisting of silver-111, silver-153, scandium-46, scandium-47, silver-111, strontium-85, strontium-89, tellurium-129, tellurium-132, terbium-160, terbium-161, thallium-201, thallium-206, thallium-210, thorium-227, thorium-231, thorium-234, tin-113, tungsten-185, tungsten-187, vanadium-48, ytterbium-169, yttrium-88, yttrium-90, yttrium-91, zirconium-95, and combinations thereof; Including, The alginate chelates a divalent cation and at least one radionuclide cation; Alginate gel, or 1. An alginate gel comprising: an alginate comprising at least one peptide having a peptide sequence for interacting with a receptor of a cell affected by a proliferative disease; Ba 2+ , Sr 2+ , Ca 2+ , Cu 2+ , Zn 2+ and combinations thereof; and Actinium-225, Actinium-228, Astatine-211, Barium-140, Bismuth-210, Bismuth-211, Bismuth-212, Bismuth-213, Calcium-45, Calcium-47, Copper-64, Francium-221, Gallium-67, Holmium-166, Indium-111, Iridium-192, Iron-59, Lead-211, Lead-212, Lead-214, Lutetium-177, Osmium-191, Osmium-193, Palladium-103, Platinum-197, Radium-223, Radium-224, Radium-225, Rhenium-186, Rhenium-188, Samarium-1 53, scandium-46, scandium-47, silver-111, strontium-85, strontium-89, tellurium-129, tellurium-132, terbium-160, terbium-161, thallium-201, thallium-206, thallium-210, thorium-227, thorium-231, thorium-234, tin-113, tungsten-185, tungsten-187, vanadium-48, ytterbium-169, yttrium-88, yttrium-90, yttrium-91, zirconium-95, and combinations thereof; and Including, The alginate, together with at least one pharma- ceutically acceptable carrier, diluent, and / or excipient, chelates a divalent cation and at least one radionuclide cation; The present invention relates to a composition comprising an alginate gel.

[0107] A gel is defined as disclosed herein. In a preferred embodiment, the gel is in the form of particles.

[0108] The alginate gels of the invention and compositions comprising said gels may be used therapeutically, such as for the delivery of radioactive decay in vivo to one or more specific sites, such as specific cells, tissues, organs, etc., with the advantages outlined above for the gels.

[0109] For the various aspects of the invention described herein relating to use as a medicament and / or treatment for disease, particularly with respect to cells infected with a proliferative disease, the cells may in all embodiments be present at a single site in the body, e.g. in the case of a localized solid tumor, or may be present at multiple sites, e.g. in the case of a distributed or metastasized cancerous disease.

[0110] Due to the cytotoxic effects of radioactive decay, the gels and compositions of the invention may be particularly useful against proliferative diseases. Thus, in a further aspect, the invention provides a method for treating proliferative diseases comprising: For use in a method of treatment of a proliferative disease, 1. An alginate gel comprising: an alginate comprising at least one peptide having a peptide sequence for interacting with a receptor of a cell affected by a proliferative disease; Ba 2+ , Sr 2+ , Ca 2+ , Cu 2+ , Zn 2+ and combinations thereof; and Actinium-225, Actinium-228, Astatine-211, Barium-140, Bismuth-210, Bismuth-211, Bismuth-212, Bismuth-213, Calcium-45, Calcium-47, Copper-64, Francium-221, Gallium-67, Holmium-166, Indium-111, Iridium-192, Iron-59, Lead-211, Lead-212, Lead-214, Lutetium-177, Osmium-191, Osmium-193, Palladium-103, Platinum-197, Radium-223, Radium-224, Radium-225, Rhenium-186, Rhenium-188, Samarium at least one radionuclide cation selected from the group consisting of silver-111, silver-153, scandium-46, scandium-47, silver-111, strontium-85, strontium-89, tellurium-129, tellurium-132, terbium-160, terbium-161, thallium-201, thallium-206, thallium-210, thorium-227, thorium-231, thorium-234, tin-113, tungsten-185, tungsten-187, vanadium-48, ytterbium-169, yttrium-88, yttrium-90, yttrium-91, zirconium-95, and combinations thereof; Including, The alginate chelates a divalent cation and at least one radionuclide cation; Alginate gel, or 1. An alginate gel comprising: an alginate comprising at least one peptide having a peptide sequence for interacting with a receptor of a cell affected by a proliferative disease; Ba 2+ , Sr 2+ , Ca 2+ , Cu 2+ , Zn 2+ and combinations thereof; and Actinium-225, Actinium-228, Astatine-211, Barium-140, Bismuth-210, Bismuth-211, Bismuth-212, Bismuth-213, Calcium-45, Calcium-47, Copper-64, Francium-221, Gallium-67, Holmium-166, Indium-111, Iridium-192, Iron-59, Lead-211, Lead-212, Lead-214, Lutetium-177, Osmium-191, Osmium-193, Palladium-103, Platinum-197, Radium-223, Radium-224, Radium-225, Rhenium-186, Rhenium-188, Samarium-1 53, scandium-46, scandium-47, silver-111, strontium-85, strontium-89, tellurium-129, tellurium-132, terbium-160, terbium-161, thallium-201, thallium-206, thallium-210, thorium-227, thorium-231, thorium-234, tin-113, tungsten-185, tungsten-187, vanadium-48, ytterbium-169, yttrium-88, yttrium-90, yttrium-91, zirconium-95, and combinations thereof; and Including, The alginate, together with at least one pharma- ceutically acceptable carrier, diluent, and / or excipient, chelates a divalent cation and at least one radionuclide cation; The present invention relates to a composition comprising an alginate gel.

[0111] A gel is defined as disclosed herein. In a preferred embodiment, the gel is in the form of particles.

[0112] The terms "treating" and "treatment" and "therapy" (and grammatical variations thereof) are used interchangeably herein and refer to 1) inhibiting a disease; for example, inhibiting a disease, condition, or disorder in a subject experiencing or exhibiting the pathology or symptomology of the disease, condition, or disorder, including prevention of the disease (i.e., prophylactic treatment, preventing further onset of the pathology and / or symptomology), or 2) alleviating the symptoms of the disease, or 3) relieving a disease; for example, relieving a disease, condition, or disorder in a subject experiencing or exhibiting the pathology or symptomology of the disease, condition, or disorder (i.e., reversing the pathology and / or symptomology). These terms may refer to the use and / or administration of pharmaceuticals, active pharmaceutical ingredients (APIs), and / or pharmaceutical grade supplements.

[0113] As used herein, the terms "administer," "administration," and "administering" refer to (1) providing, giving, administering, and / or prescribing a formulation, preparation, or composition according to the present disclosure by or under the direction of a medical practitioner or his / her authorized representative, or by self-administration, and (2) introducing, ingesting, or consuming a formulation, preparation, or composition according to the present disclosure into the subject himself / herself. In a preferred embodiment, use includes administration of the alginate gel or composition by a medical practitioner or his / her authorized representative.

[0114] As used herein, "subject" means any human or non-human animal selected for treatment or therapy, and includes, and may be limited to, a "patient." None of these terms should be construed as requiring the supervision (regular or otherwise) of a medical professional (e.g., physician, nurse, nurse practitioner, physician's assistant, janitor, clinical trial investigator, etc.) or a scientific researcher.

[0115] The subject is preferably a human subject. The subject may be male or female. In some embodiments, the subject is an adult (i.e., 18 years of age or older). In certain embodiments, the subject is an elderly person. In certain embodiments, the subject is not elderly. The subject is preferably a subject diagnosed with a proliferative disease, such as cancer.

[0116] The targeted diseased tissue may be a soft tissue site, a calcified tissue site, or multiple sites, which may all be in soft tissue, all in calcified tissue, or may include at least one soft tissue site and / or at least one calcified tissue site. In one embodiment, at least one soft tissue site is targeted. The site of targeting and the site of origin of the disease may be the same, but may alternatively be different. If more than one site is involved, this may include the site of origin, or may be multiple secondary sites.

[0117] The term "soft tissue" is used herein to denote tissue that does not have a "hard" mineralized matrix. In particular, soft tissue as used herein can be any tissue that is not a skeletal tissue. Correspondingly, "soft tissue disease" as used herein refers to a disease that occurs in "soft tissue" as used herein. The present invention is particularly suited to the treatment of cancer and "soft tissue disease" and thus encompasses carcinomas, sarcomas, myelomas, leukemias, lymphomas and mixed cancers that arise in any "soft" (i.e. non-calcified) tissue, as well as other non-cancerous diseases of such tissues. Cancerous "soft tissue disease" includes solid tumors that arise in soft tissue as well as metastatic and micrometastatic tumors. In fact, a soft tissue disease may include a primary solid tumor of soft tissue and at least one metastatic tumor of soft tissue in the same patient. Alternatively, a "soft tissue disease" may consist of only solid tumors or only metastases where the primary tumor is a skeletal disease.

[0118] In certain embodiments, the method of treatment or use in the method of treatment includes treatment with the alginate gel of the present invention in conjunction with surgery, such as cancer surgery. For example, as part of a surgical procedure in which cancerous tissue is removed or removed, the alginate gel is administered to the area of ​​cancer, such as the cavity in which the cancerous tissue is removed. Preferably, such administration and treatment is performed as part of a surgical procedure, simultaneously with surgery or immediately after surgery. Thus, the administered radionuclide delivers radioactive decay to the specific site where the cancerous tissue is removed, and the administered radionuclide cation and / or its daughter nuclide can provide their toxic effects to tissues and cells in the treatment area.

[0119] When the gel or composition of the present invention is used as a medicament and / or in a treatment method according to the present invention, at least one peptide having a peptide sequence for interacting with a receptor of cells affected by a proliferative disease is selected, for example based on Table 1, so as to be suitable for interacting with (e.g., binding to) a receptor of cells affected by the specific proliferative disease to be treated.

[0120] In some embodiments, the proliferative disease is cancer, a non-cancerous tumor, a neoplastic disease, or a hyperplastic disease. In some embodiments, the proliferative disease is selected from the group of atherosclerosis, rheumatoid arthritis, psoriasis, idiopathic pulmonary fibrosis, scleroderma, and cirrhosis of the liver.

[0121] In certain embodiments, the aforementioned proliferative disease is cancer. As used herein, the terms "cancer" and "tumor" refer to any neoplastic growth in a subject, including primary tumors and any metastasis. Cancer can be liquid or solid tumor type. Liquid tumors include tumors of blood origin, including, for example, myeloma (e.g., multiple myeloma), leukemia (e.g., Waldenstrom's syndrome, chronic lymphocytic leukemia, other leukemias) and lymphomas (e.g., B-cell lymphoma, non-Hodgkin's lymphoma). Solid tumors can originate from organs, including, but not limited to, lung, brain, breast, prostate, ovarian, colon, kidney and liver cancer.

[0122] In some embodiments, the cancer is selected from the list including or consisting of lung cancer, pancreatic cancer, colorectal cancer, liver cancer, glioma, renal cancer, non-Hodgkin's lymphoma, neuroblastoma, CNS metastasis, peritoneal cancer, follicular lymphoma, colorectal cancer, small cell lung cancer, carcinoma, sarcoma, myeloma, leukemia, lymphoma, prostate cancer, or mixed cancer.

[0123] In certain embodiments, the cancer is a metastatic cancer. Although metastatic cancer is notoriously difficult to treat using conventional anti-cancer therapies, the targeted alginate vehicles of the present invention represent a promising line of treatment for such cancers.

[0124] The gel or composition for use as a medicament and / or in a method of treatment according to the present invention is administered to a subject in a therapeutically effective dose. The term "therapeutically effective dose" as used herein means an amount of the gel according to the present invention effective to bring about a desired therapeutic effect in a subject with a reasonable benefit / risk ratio applicable to any treatment. The therapeutically effective dosage may vary depending on the route of administration and the dosage form. Furthermore, the dosage may depend on the particle used, the type of radioactive decay of the radionuclide cation and / or its daughter nuclide, the stage of the condition, the age and weight of the subject, etc., and may be routinely determined by the skilled artisan according to principles well known in the art.

[0125] In some embodiments, the amount of radionuclide cation used per patient dose may be in the range of 1 kBq to 10 GBq, preferably 1 kBq to 100 MBq, more preferably 10 kBq to 25 MBq, even more preferably 10 kBq to 10 MBq. Dosages and maximum dosages can be determined by one of skill in the art based on general knowledge of appropriate dosages and maximum dosages. It is recognized in the art that realistic and conservative estimates of toxic side effects of daughter isotopes must be adopted.

[0126] In some embodiments, the particles are administered at a dosage of 10 Bq / kg-100 MBq / kg body weight. Correspondingly, a single dosage unit may contain any of these ranges multiplied by the appropriate body weight, e.g., 30-150 Kg, preferably 50-100 kg. The dosage may depend on the radionuclide, its half-life and / or the selection of the particular progeny. The dosage, gel and route of administration may be such that the dosage of progeny generated in vivo is less than 300 kBq / kg, e.g., less than 200 kBq / kg, preferably less than 150 kBq / kg, e.g., less than 100 kBq / kg.

[0127] The alginate gel or composition for use as a medicament and / or in a method of treatment according to the present invention can be administered locally or systemically. The gel or composition according to the present invention can be administered by a route of administration selected from the group consisting of or including intratumoral, intrathecal, intravenous, and intraarterial, such as embolization therapy. The choice of the route of administration can be selected based on the form of the gel. For intravenous administration, the gel must be in the form of nanoparticles.

[0128] The therapeutically effective dose of the alginate gel or composition according to the invention can be administered in a single dose or divided doses. The alginate gel or composition according to the invention can be administered once a day, more than once a day, once every two days, once every three days, twice a week or once a week, or as deemed appropriate by a medical professional. In certain embodiments, the alginate gel or composition according to the invention is administered once a day. In other embodiments, the alginate gel or composition according to the invention is administered twice a day. In some embodiments, the administration regimen is predetermined and is the same across a patient population. In other embodiments, the dosage and frequency of administration of the alginate gel or composition according to the invention treatment is determined by a medical professional based on factors including, but not limited to, the stage of the disease, the severity of symptoms, the route of administration, the age, weight, general health, sex and / or diet of the subject, and / or the subject's response to the treatment.

[0129] In some embodiments, the therapeutically effective dose is administered at regular intervals. In other embodiments, the dose is administered as needed or sporadically. The alginate gel or composition according to the invention may be administered by a medical professional. The alginate gel or composition according to the invention may be administered with or without food, depending on factors such as the formulation and route of administration. In some embodiments, the alginate gel or composition according to the invention is administered at a specific time of day.

[0130] In some embodiments, the alginate gel or composition is administered orally. In some embodiments, the alginate gel or composition is administered with or before a meal. In some embodiments, the alginate gel or composition according to the invention is administered intravenously. In these embodiments, water is a particularly useful excipient. Saline solutions and aqueous dextrose and glycerol solutions can also be used as liquid excipients, particularly for injectable solutions.

[0131] A preferred unit dosage formulation is one that contains a therapeutically effective dose or a suitable fraction thereof of the gel according to the present invention as described herein above. The compositions of the present invention may be provided in unit dosage form as a single dose in which all active and non-active ingredients are combined in a suitable system and there is no need to mix the ingredients before administration. Alternatively, the compositions may be provided as a kit, such as the kits disclosed above, and may include instructions for storing, preparing, administering and / or using the composition.

[0132] In some embodiments, the duration of use of the alginate gel or composition for use as a medicine and / or in a treatment method according to the invention is determined by the observed effects of the treatment, such as the reduction and / or amount of target antigen expression. In some embodiments, the treatment is continued until no further improvement can be expected. In certain embodiments, the duration of treatment with the alginate gel or composition according to the invention is at least 2 weeks, at least 1 month, at least 3 months, such as 3 months, 6 months, 9 months, 1 year, 3 years, 5 years. In other embodiments, the duration is determined by a medical professional based on factors including, but not limited to, the nature and severity of the symptoms, the route of administration, the subject's age, weight, general health, sex and / or diet, and / or the subject's response to the treatment.

[0133] In certain embodiments, the alginate gel or composition according to the invention is administered alone. In other embodiments, the alginate gel or composition according to the invention is administered in combination with one or more other therapeutic agents. The one or more other therapeutic agents may be known to have an effect on a proliferative disease, such as cancer, and / or may have an additive or synergistic mechanism of action with the alginate gel or composition according to the invention for the treatment of said proliferative disease, such as cancer. In some embodiments, the alginate gel or composition according to the invention is administered as part of a combination therapy. A combination therapy comprising an alginate gel or composition according to the invention may refer to a composition comprising an alginate gel or composition according to the invention in combination with one or more therapeutic agents, and / or the simultaneous administration of an alginate gel or composition according to the invention with one or more therapeutic agents, where the alginate gel or composition according to the invention and the other therapeutic agent(s) are not formulated in the same composition. When separate formulations are used, the alginate gel or composition according to the invention may be administered simultaneously with, intermittently, alternately, before, after, or a combination thereof with the administration of another therapeutic agent.

[0134] Embodiments and features described in the context of one aspect, e.g. directed to an alginate gel or composition, also apply to other aspects of the invention, such as its use as a medicament or in a method of treatment.

[0135] In a further aspect, the present invention provides a method of treatment, comprising administering an effective amount of a gel or composition of the present invention to a subject in need thereof.

[0136] In a further aspect, the present invention provides a method for treating a proliferative disease, comprising administering to a subject in need thereof an effective amount of a gel or composition of the present invention.

[0137] In a further aspect, the present invention provides the use of a gel or composition of the invention as a medicament.

[0138] In a further aspect, the present invention provides the use of a gel or composition of the present invention for treating a proliferative disease.

[0139] In a further aspect, the present invention provides a method for producing a method for treating a cancer cell comprising the steps of: For use as a medicine, A kit comprising: In a first container, at least one peptide having a peptide sequence for interacting with a receptor of a cell affected by a proliferative disease; Ba 2+ , Sr 2+ , Ca 2+ , Cu 2+ , Zn 2+ and at least one divalent cation selected from the group consisting of Alginate, including an alginate gel comprising Optionally, with a suitable solvent Including, In a second container, at least one radionuclide cation; With a suitable solvent A kit is provided, comprising:

[0140] In a further aspect, the present invention provides a method for producing a method for treating a cancer cell comprising the steps of: For use in treating a proliferative disorder, A kit comprising: In a first container, at least one peptide having a peptide sequence for interacting with a receptor of a cell affected by a proliferative disease; Ba 2+ , Sr 2+ , Ca 2+ , Cu 2+ , Zn 2+ and combinations thereof; and Alginate, including an alginate gel comprising Optionally, with a suitable solvent Including, In a second container, at least one radionuclide cation; With a suitable solvent A kit is provided, comprising:

[0141] In a further aspect, the present invention provides a method for producing a method for treating a cancer cell comprising the steps of: For use as a medicine, A kit comprising: In a first container, A water-soluble alginate comprising: The alginate comprises at least one peptide having a peptide sequence for interacting with a receptor of a cell affected by a proliferative disease, A water-soluble alginate; Water, Optionally, with another suitable solvent Including, In a second container, A water-insoluble particle, the particle being composed of an alginate and Ba. 2+ , Sr 2+ , Ca 2+ , Cu 2+ , Zn 2+and combinations thereof; and Water and Including, In a third container, at least one radionuclide cation; With a suitable solvent A kit is provided, comprising:

[0142] In a further aspect, the present invention provides a method for producing a method for treating a cancer cell comprising the steps of: For use in treating a proliferative disorder, A kit comprising: In a first container, A water-soluble alginate comprising: The alginate comprises at least one peptide having a peptide sequence for interacting with a receptor of a cell affected by a proliferative disease, A water-soluble alginate; Water, Optionally, with another suitable solvent Including, In a second container, A water-insoluble particle, the particle being composed of an alginate and Ba. 2+ , Sr 2+ , Ca 2+ , Cu 2+ , Zn 2+ and combinations thereof; and Water and Including, In a third container, at least one radionuclide cation; With a suitable solvent A kit is provided, comprising:

[0143] The present invention is not limited to the embodiments and examples shown. Although various embodiments of the present disclosure are described herein, it will be apparent to those skilled in the art that such embodiments are provided merely as examples. Numerous modifications and changes to the embodiments described herein, as well as variations and substitutions, will be apparent to those skilled in the art without departing from the present disclosure. It should be understood that various alternatives to the embodiments described herein can be used in practicing the present disclosure.

[0144] It is to be understood that all embodiments of the present disclosure may be optionally combined with any one or more of the other embodiments described herein.

[0145] It is to be understood that each component, compound, particle or parameter disclosed herein should be construed as disclosed for use alone or in combination with one or more of any and all other components, compounds or parameters disclosed herein. Each amount / value or amount / value range of each component, compound or parameter disclosed herein should also be construed as disclosed in combination with each amount / value or amount / value range disclosed for any other component, compound or parameter disclosed herein, and thus, it is to be further understood that any combination of amount / values ​​or amount / value ranges of two or more components, compounds or parameters disclosed herein is also disclosed in combination with each other for the purposes of this specification. Any feature described herein, and combinations of such features, are included within the scope of the present invention, unless the features are mutually inconsistent.

[0146] It should be understood that each lower limit of each range disclosed herein should be interpreted as being disclosed in combination with each upper limit of each range disclosed herein for the same component, compound, or parameter. Thus, a disclosure of two ranges should be interpreted as a disclosure of four ranges derived by combining each lower limit of each range with each upper limit of each range. A disclosure of three ranges should be interpreted as a disclosure of nine ranges derived by combining each lower limit of each range with each upper limit of each range. Furthermore, a specific amount / value of a component, compound, or parameter disclosed in the specification or examples should be interpreted as a disclosure of either a lower or upper limit of a range, and thus can be combined with any other lower or upper limit or range or specific amount / value of that component, compound, or parameter disclosed elsewhere in this application to form a range for the same component, compound, or parameter. EXAMPLES

[0147] Example 1: Preparation of alginate gel particles Sodium alginate (PRONOVA LVG) was first dissolved in distilled water to obtain a 2% solution. Alginate gel particles in the form of microspheres with an average diameter of 150 μm were formed using a NISCO electrostatic bead generator (model VAR1) with a 0.1 mm (for bead diameter 150 μm) nozzle, a flow rate of 2-5 ml / h, an electrostatic potential of 6500 kV between the nozzle and the gelling bath and a distance of about 1.5 cm from the nozzle to the surface of the gelling bath. The gelling bath contained a 50 mM aqueous solution of CaCl2. Figure 2 shows a micrograph of the obtained alginate gel microspheres, taken by a digital camera attached to the phototube of a Nikon microscope.

[0148] In the following examples, both M-rich alginate (identified as LVM) and G-rich alginate (identified as LVG) were used. In some of the examples, sodium alginate (PRONOVA LVG or PRONOVA SLG) was used. The examples using sodium alginate can also be considered representative examples of peptide-linked alginate, as conjugation of peptides typically does not affect the gelling ability of alginate. Commercially available NOVATACH peptide-linked alginate contains 0.8-0.4% peptide (either GRGDSP or GGGGRGDSP). This low peptide:alginate ratio does not affect the functionality of the alginate, including its ability to chelate radionuclide cations. Other examples presented herein used NOVATACH peptide-linked alginate where appropriate.

[0149] Example 2: Binding of Ra-223 and daughter nuclides to calcium cross-linked homogeneously gelling alginate microspheres - an example of a divalent radionuclide cation In this example, the binding of Ra-223 and daughter nuclides to calcium cross-linked homogelling alginate microspheres and the stability of such binding were investigated.

[0150] A known amount of preformed alginate gel microspheres was washed successively to remove excess gelling ions using 0.9% NaCl solution in 8N HNO3. 223Radium-223, present as RaCl2, was diluted in an aliquot of phosphate-buffered saline (PBS). The radioactivity content of this solution (measured as Bq / ml) was determined by a dose calibrator (Capintec). Approximately 600 mg of alginate microspheres (by weight) were then mixed with approximately 300 kBq / mL of radioactivity. For the binding of radium isotopes, room temperature conditions, intermittent shaking and 60 min of incubation conditions were found to be sufficient to bind all available radium and the decay daughter nuclides of radium-223, lead-211 and bismuth-211. The Ra-223-coated alginate gel microspheres were then washed three times with PBS. The radioactivity associated with the alginate microspheres was determined by gamma spectroscopy using a high-performance germanium detector (HPGe) capable of simultaneously detecting radium-223 and the daughter radionuclides lead-2111 and bismuth-211. The radionuclide-coated alginate gel microspheres were stored in PBS solution.

[0151] The radioactivity from bound radium-223 and its decay daughter nuclides in samples containing a similar weight (500 mg) of alginate microspheres was then determined using HPGe, measured for samples containing a similar weight (500 mg) of alginate microspheres. Figures 3-5 show the results from these measurements. In the figures, "Ra-223 solution" indicates the sample without alginate microspheres, "LVG" indicates G-rich alginate, and "LVM" indicates M-rich alginate. The data (kBq / sample versus date of analysis) were plotted using GraFit software. The slope of the curve represents the radioactive decay of the radionuclide.

[0152] As can be seen, alginate microspheres bind radium-223 and decay daughter nuclides, but there appears to be a constant release of the radionuclides from the gel network over time, as indicated by the steeper slope of the bound radioactivity curve versus the curve for radionuclide in solution over time. Furthermore, M-rich alginate (LVM) appears to have an even reduced ability to retain the daughter decay radionuclides. This indicates weaker binding of radium-223 and decay daughter nuclides to LVM alginate, but radionuclide binding nevertheless occurs.

[0153] In this example, microspheres were formed using homogeneous gelation of alginate, i.e., NaCl to Na + There were non-gelling ions present in the form of Na. Examples 3 and 4 below demonstrate the effect of producing alginate microspheres by a heterogeneous gelling technique, i.e. + does not exist.

[0154] In this example, radium-223 was used, however, similar conditions and results may be obtained using other radionuclides.

[0155] Example 3: Binding of radionuclides and decay daughter nuclides to strontium cross-linked heterogeneous gelling alginate microspheres Radium-223 and its decay daughter radionuclides In this part of Example 3, the binding of Ra-223 and daughter nuclides to strontium cross-linked heterogeneous gelling alginate microspheres and the stability of said binding were investigated.

[0156] Alginates (LVG and LVM) at a concentration of 2% in distilled water were gelled using a gelling bath containing 50 mM SrCl2 in distilled water and no NaCl. 2+The absence of non-gelling ions results in a non-uniform gelling process. The microspheres were washed three times with PBS and then resuspended in 1 mL of PBS. A certain amount of radium-223, which is in equilibrium with its daughter radionuclides, was added and incubated with the microspheres for 60 min at room temperature. Figures 6-8 show the binding of radium-223 and the decay daughter radionuclides lead-211 and bismuth-211 to the resulting microspheres. In the figures, "Ra-223 solution" represents a sample without alginate microspheres and is a control for the decay rate of the radionuclides alone. The radioactivity in the radionuclide solution associated with the alginate microspheres was determined by a high purity germanium detector (HPGe). The obtained data (kBq / sample) were plotted against the date of measurement using GraFit software. The slope of the curve represents the radioactive decay of the radionuclides.

[0157] The curves in Figures 6-8 show that despite the change in gelling ion from calcium to strontium compared to Example 2, Ra-223 was still able to bind to the alginate gel microspheres. The results also show that the particles resulting from the heterogeneous gelling process bind and retain the radionuclide cation more efficiently than the homogeneous gelling process used in Example 2, as evidenced by the slope of the radioactive decay curve being nearly identical to the radionuclide-only decay curve. This is an indication that the microspheres made by the heterogeneous gelling method do not release radium-223 or the decay daughter radionuclides over time. It is also evident that the decay daughter radionuclides are not released from the alginate network and are retained throughout the radioactive decay.

[0158] Actinium-225 and its decay daughter radionuclides In the second part of Example 3, the ability of strontium cross-linked alginate microspheres to bind 225-Ac and its decay daughter species 221-Fr and 213-Bi was investigated. Uniform calcium cross-linked alginate microparticles were produced using PRONOVA LVG alginate (1%) as described in Example 1, where the gelling bath consisted of 50 mM SrCl2 in purified water. The diameter of the strontium cross-linked alginate microparticles was approximately 230 μm. Prior to use, the alginate microparticles were washed in Dulbecco's phosphate buffered saline (D-PBS) to remove excess non-cross-linked Sr. 2+ ions were removed. For absorption, triplicate samples containing known amounts of strontium cross-linked alginate microparticles with 225-Ac (approximately 270 mg in triplicate) were suspended in D-PBS (500 μL) containing approximately 2 kBq of 225-Ac and incubated at room temperature for 1 h. After incubation, the microparticles were centrifuged and the supernatant was removed to analyze the residual radioactivity. Subsequently, the microparticles were washed three times using 500 μL portions of D-PBS and finally resuspended in 500 μL of D-PBS, transferred to RIA tubes, and counted using a Cobra II NaI gamma counter. The gamma counter was set with detector channels corresponding to total radioactive energy (15–2000 keV), 180–260 keV (221-Fr), and 400–500 keV (213-Bi).

[0159] The results, shown graphically in Figure 9, show that 1) the 225-Ac solution used contained the decay daughter radionuclides 221-Fr and 213-Bi as well, and 2) the strontium cross-linked alginate microparticles were able to bind not only 225-Ac but also the decay daughter radionuclides 221-Fr and 213-Bi. The relative amount of bound radionuclides was about 40% of the total radioactivity added. However, the bound radioactivity of the strontium cross-linked alginate microparticles was not corrected for the amount of alginate present, i.e., the amount of alginate microparticles in each sample was about 270 mg, and the amount of alginate was only 1%, resulting in a weight of 2.7 mg of alginate). The samples were stored at room temperature for 14 days and radioactivity was analyzed in samples washed with D-PBS. Figure 9 also shows that the decay daughter radionuclides 221-Fr and 213-Bi are retained by the alginate microparticles. This indicates that the formation of 221-Fr from the decay of 225-Ac, as well as the subsequent decay of 221-Fr to form 217-At (not detected due to weak gamma energy) and further to 213-Bi, are both retained by the alginate microparticles and are not released from the alginate network, but are retained throughout the radioactive decay. This demonstrates the chelating ability of alginate for 225-Ac and the decay daughter radionuclides, as well as the retention of the decay daughter radionuclides within the alginate microparticles.

[0160] Example 4: Binding of Ra-223 and daughter nuclides to barium cross-linked heterogeneous gelling alginate microspheres In this example, the binding of Ra-223 to barium cross-linked heterogeneous gelling alginate microspheres and the stability of such binding were investigated.

[0161] Alginates (LVG and LVM) at a concentration of 2% in distilled water were gelled using a gelling bath containing 50 mM BaCl2 in distilled water and no NaCl. 2+The absence of non-gelling ions results in a non-uniform gelling process. The microspheres were washed three times with phosphate-buffered saline (PBS) and then resuspended in 1 mL of PBS. A constant amount of radium-223, which is in equilibrium with its daughter radionuclides, was added and incubated with the microspheres for 60 min at room temperature. Figures 10-12 show the binding of radium-223 and the decay daughter radionuclides lead-211 and bismuth-211 to the resulting microspheres. In the figures, the slope of the curve represents the radioactive decay of the radionuclides. "Ra-223 solution" shows a sample without alginate particles and is a control for the decay rate of the radionuclides alone. The radioactivity in the radionuclide solution associated with the alginate microspheres was determined by a high purity germanium detector (HPGe). The obtained data (kBq / sample) were plotted against the measurement date using GraFit software.

[0162] The results of Example 4 compared to those of Example 2 also show that the gel obtained by the heterogeneous gelation process binds and retains the radionuclide cations more efficiently than the gel obtained by the homogeneous gelation process used in Example 2, as evidenced by the slope of the radioactive decay curve being nearly identical to the radionuclide-only decay curve (Figure 9). This is a further indication that the microspheres produced by the heterogeneous gelation method do not release radium-223 or the decay daughter nuclides over time. Furthermore, it is evident from Figures 11-12 that the decay daughter radionuclides lead-211 and bismuth-211 are also not released from the alginate network and are retained throughout the radioactive decay.

[0163] In the above examples, radium-223 and 225-Ac were used, however, similar conditions and results may be obtained using other radionuclides.

[0164] Example 5: Binding of lutetium-177 to calcium cross-linked heterogeneous gelling alginate microspheres In this experiment, the binding of trivalent radionuclide cations to alginate microspheres was studied.

[0165] Calcium cross-linked heterogeneous alginate gel microspheres were produced from a 2% sodium alginate solution (PRONOVA LVG sodium alginate) in deionized water that was electrostatically delivered to a gelling bath composed of 50 mM CaCl2 in deionized water. The preformed alginate gel microspheres (2.2 grams) were then washed with 0.9% NaCl and then divided into three separate samples. The samples were then washed with 0.9% NaCl and then divided into three separate samples. 177 Lu 3+ (beta-emitting radionuclide) solution for 1 h. After incubation, the alginate gel microspheres were washed three times with 0.9% NaCl and then the incorporated radioactivity was measured using a NaI detector. Results are given as uncorrected counts per minute. [Table 2]

[0166] As can be seen in Table 2, of the available radioactivity, approximately 56% was bound to the preformed alginate gel microspheres, as shown below in Table 1. Thus, the gel was capable of chelating trivalent radionuclide cations.

[0167] Example 6: Binding of Thorium-227 to Calcium Cross-Linked Heterogeneous Gelling Alginate Microspheres In this experiment, the binding of tetravalent radionuclide cations to alginate microspheres was studied.

[0168] Calcium cross-linked heterogeneous gelling alginate microspheres were prepared in the same manner as described in Example 5 above. The microspheres were washed three times with 0.9% NaCl solution, resuspended in 0.8% NaCl, and 227 Th 4+Of the available radioactivity, approximately 30% was bound to the preformed alginate microspheres (Table 3). 227 Available radionuclides produced during radioactive decay of Th (the daughter radionuclide) 223 Ra, 211 Pb and 211 It is shown that 100% of Bi binds to preformed alginate microspheres after 1 hour of incubation. [Table 3]

[0169] In an additional experiment, conducted in the same manner as above, the binding of thorium-227 and decay daughter nuclides to guluronic acid-rich alginate (LVG) and mannuronate-rich alginate (LVM) after a 2-hour incubation period was evaluated to replicate the findings in Table 3. Heterogeneous gelation was used to produce calcium cross-linked alginate microspheres. An equivalent amount (mg) of microspheres was washed with 0.9% NaCl and then incubated with a solution of thorium-227 for 2 hours. The results are summarized below (Table 4) and show that after a 2-hour incubation period, there was no available 227 38.8% of Th was bound to and available in G-rich (LVG) alginate gel microspheres. 227 It shows that 20.4% of Th was bound to alginate gel microspheres made from M-rich (LVM) alginate. [Table 4]

[0170] It can be concluded that alginate gels are capable of binding tetravalent radionuclide cations. The results of the latter experiment showed that after a 2-hour incubation period, 38.8% of the available thorium-227 was bound to the alginate microspheres. The results shown in Table 3 showed that 37.7% of the available thorium-227 was bound to the microspheres. The percentage of thorium-227 bound to the alginate microspheres is essentially the same between the two experiments. The results are also consistent with the finding that G-rich alginate can chelate thorium-227 more efficiently than M-rich alginate due to an increased number of guluronic acid monomers in the alginate polymer molecule. This is shown by the fact that microspheres made using G-rich LVG alginate bound 37.7% of the available thorium-227, whereas only 20.4% of the available thorium-227 was bound to microspheres made using M-rich LVM alginate.

[0171] Example 7: Calcium alginate microparticles incorporate radionuclide cations and retain decay daughter nuclides This example demonstrates that dry microparticles of calcium alginate can also bind radionuclides and retain daughter nuclides. Calcium alginate was produced by conversion of sodium alginate powder suspended in isopropyl alcohol by adding an aqueous solution of calcium chloride, as exemplified in U.S. Patent Application Publication No. 2011 / 0053886, incorporated herein.

[0172] Radium-224 and its decay daughters 13μm mean size distribution (Dv 50A 30 mg sample of calcium alginate microparticles with 100 μl of water was first resuspended in 200 μl of water, then 150 μl of radium-224 solution was added, followed by another 150 μl of water. The sample was vortex mixed and then incubated at room temperature for 30 minutes. An aliquot of 500 μl of water was added to the particle suspension. The sample was vortex mixed and then centrifuged at 6000 rpm for 1 minute. The supernatant was transferred to another Eppendorf tube labeled Wash 1. The particle sample was then resuspended in 1000 μl of water, vortexed, and then centrifuged. The supernatant was transferred to an Eppendorf tube labeled Wash 2. The wash with 1000 μl of water was repeated and the supernatant was collected and placed in tube Wash 3. The sample was then analyzed for radioactivity using a high purity germanium detector.

[0173] The samples were kept at room temperature and analyzed again on the 1st day (24 hours after labeling) and on the 12th day after labeling. Radioactivity was measured after first washing the particles with water. The results are shown in Table 5. [Table 5]

[0174] The radioactive half-life of 224-Ra is t 1 / 2 = 3.66 days, t of 212-Pb 1 / 2 = 10.6 hours, t of 212-Bi 1 / 2 = 60.5 min, t of 208-Tl 1 / 2 = 32 min. The solution of 224-Ra used was in a long-term equilibrium state, meaning that the decay daughter radionuclides 212-Pb, 212-Bi, and 208-Tl were present in constant amounts in solution. This solution represents the available radioactivity and radionuclide added to the calcium alginate microparticles. After incubation and washing to remove unbound radioactivity, the radioactivity associated with the alginate microparticles was measured again for each decay daughter radionuclide. The % bound radioactivity relative to the available radioactivity was calculated. It can be seen that approximately 90% of the available radioactivity emitted from each radionuclide was bound to the alginate microspheres.

[0175] One day after labeling, the particles were washed and the radioactivity was measured (HPGe detector) and, using a available radioactive decay calculator (http: / / www.radprocalculator.com), the amount of 224-Ra radioactivity theoretically remaining associated with the alginate microparticles was calculated. The calculations indicate that of the original 8720 Bq of 224-Ra associated with the alginate microparticles on day 0 immediately after labeling, there would be 7232 Bq of 224-Ra if the microparticles retained all of the bound radioactivity. The decrease in radioactivity from 8720 Bq to 7232 Bq represents the natural decay of 224 radium. The radioactivity associated with the alginate microparticles on day 1 after labeling was measured to be 7270 Bq, so 100% of the radioactivity was still associated with the microparticles conditioned to decay after 1 day.

[0176] NOTE: The daughter radionuclides 212-Pb, 2121-Bi and 208-Tl are being continuously produced as a result of the radioactive decay of 224-Ra. Therefore, these data are not used to calculate the % bound radioactivity. Finally, the spontaneous decay of 224-Ra 12 days after labeling was calculated to be 900 Bq, reduced from 8740 Bq. The measured radioactivity associated with the alginate microparticles was 913 Bq, which is also 100% of the radioactivity adjusted for the decay of 224-Ra. The conclusion is that calcium alginate microparticles effectively bind radionuclides, including the decay daughter nuclides, and remain bound to the radionuclides.

[0177] Actinium-225 and its decay daughters In the first experiment, triplicate 50 mg calcium alginate microparticle samples were resuspended in a solution containing 20 kBq of 225-Ac and incubated for 1 h at room temperature. The samples were then centrifuged and the supernatants transferred to individual RIA tubes. 500 μL of purified water was added to each sample and the particles were resuspended. The samples were centrifuged and the supernatants, corresponding to the wash solution, were transferred to individual RIA tubes. Finally, 500 μL of purified water was added to each calcium alginate microparticle sample and the resulting suspensions were transferred to individual RIA tubes. The gamma radioactivity of all tubes was counted using a Cobra II NaI gamma counter with detector channels corresponding to total radioactive energy (15–2000 keV), 180–260 keV (221–Fr), and 400–500 keV (213–Bi). After the initial gamma count, the calcium alginate samples were further incubated at room temperature. Samples were centrifuged, the supernatants collected, washed (and collected) and resuspended in purified water at specified time points up to 31 days.

[0178] The results shown in Figure 13 compare the radioactivity counts (as CPM) associated with calcium alginate microparticles to those of an equivalent 20 kBq solution of 225-Ac without microparticles. The first conclusion is that the 225-Ac solution (without calcium alginate microparticles) is in equilibrium with the decay daughter radionuclides 221-Fr and 213-Bi. However, the radioactivity associated with calcium alginate microparticles also indicates the presence of 225-Ac as well as the two decay daughter radionuclides 221-Fr and 213Bi. This same pattern is seen at all time points, i.e., calcium alginate microparticles bind 225-Ac and retain 221-Fr and 213Bi formed from the radioactive decay of 225-Ac. Since 213-Bi is generated from 217-At, the data indicate that this decay daughter nuclide must also be retained by calcium alginate microparticles, even if it is not detected due to its very weak gamma energy. Another conclusion drawn from the data presented in Figure 13 is that greater than 90% of the available radioactivity was associated with the microparticles at all time points, demonstrating that alginate is an effective chelator of 225-Ac and its decay daughter radionuclides.

[0179] In the second experimental setup, 10 mg samples of calcium alginate microparticles were suspended in various amounts (µL) of aqueous 225-Ac corresponding to approximately 9.4, 18.8, 47, and 94 kBq / mL in a total volume of 1000 µL and incubated at room temperature for 1 h. The samples were then centrifuged, the supernatant transferred to an RIA tube, and the calcium alginate pellet resuspended in 1000 µL of purified water. After centrifugation, the resulting washes were also transferred to separate RIA tubes, and the pellets resuspended in 1000 µL of purified water and transferred to separate RIA tubes. All samples were counted using a Cobra II NaI gamma counter with detector channels corresponding to total radioactive energy (15–2000 keV), 180–260 keV (221–Fr), and 400–500 keV (213–Bi). After the initial gamma counting, the calcium alginate samples were further incubated at room temperature. Samples were centrifuged, the supernatants collected, washed (and collected), and resuspended in purified water at specified time points up to 31 days. Results showing counts (CPM) versus amount of 225-Ac added are shown in Figure 14 for 225-Ac (total radioactive counts), Figure 15 for 221-Fr, and Figure 16 for 213-Bi.

[0180] For all calcium alginate samples and all time points, over 90% of the available radioactivity was associated with the microparticles, and less than 1% was associated with the supernatant or washings. Furthermore, as the amount (volume) of 225-Ac added to the calcium alginate microparticles increased, i.e., the radioactivity concentration increased, the amount of radioactivity associated with the microparticles also increased. As no plateau was reached for radioactivity incorporation, saturation of binding of 225-Ac and its decay daughter radionuclides was not reached. Thus, there is additional capacity for calcium alginate microparticles to bind 225-Ac and its decay daughter radionuclides. This has practical implications for formulating amounts of calcium alginate microparticles with sufficient therapeutic radioactivity.

[0181] Example 8: Alginate gel stability The purpose of this example was to demonstrate that the degradability of alginate gels can vary based on the composition of the alginate gel.

[0182] Various formulations of alginate gels were cast into wells of a 12-well tissue culture plate and allowed to sit at room temperature for 2 hours. The formulations consisted of different alginates: formulation 3 used PRONOVA LVM sodium alginate; formulation 24 used sterile PRONOVA SLM20 alginate; formulation 25 used PRONOVA LVG alginate. The alginates were dissolved in deionized water to give a 2% solution. The gelling ion was calcium dissolved in deionized water. The gels were weighed on day 0 and each was placed into a separate pre-weighed 50 mL plastic centrifuge tube labeled with the formulation number, with three gels in each formulation and one gel in each centrifuge tube. 20 mL of 0.9% NaCl solution was added to each centrifuge tube and the tubes were placed in a shaking incubator at 30°C and 100 rpm. The 0.9% NaCl solution was changed daily. The gels were weighed on various days after preparation by removing the NaCl solution and weighing the tube containing the gel. The weight of the gel was calculated by subtracting the weight of the tube from the weight of the tube + gel. Data points in Figure 12 represent the average of three gels of each formulation.

[0183] Referring to FIG. Formulation 3 (PRONOVA LVM): It took 24 days for the gel in Formulation 3 to dissolve. By day 28, the gel was completely dissolved.

[0184] Formulation 24 (PRONOVA SLM20): The gel in formulation 24 took 75 days to dissolve, and by day 76 the gel was completely dissolved.

[0185] Formulation 25 (PRONOVA LVG): The gel in Formulation 25 took 118 days to dissolve, and by day 120 the gel was completely dissolved.

[0186] The results show that the stability of alginate gels can be modified by modifying the formulation. G-rich alginates formed gels with the longest stability, while M-rich alginate LVM yielded the shortest stability. PRONOVA SLM20 is a sterile, freeze-dried alginate. This alginate also formed gels, with stability between LVM and LVG alginates.

[0187] Example 9 - FITC-RGD conjugation to MDCK cells This example was carried out to examine the binding of RGD peptide to cells.

[0188] MDCK cells (Madin Darby canine kidney, ATCC CCL-34) were trypsinized and counted, and a volume equivalent to 500,000 cells was transferred to a 15 mL centrifuge tube. The cells were centrifuged and the supernatant removed, after which FITC-RGD peptide was added to the cells. The cells were incubated at 37° C. for 30 minutes, then centrifuged and the supernatant removed. The cells were washed three times with PBS, with centrifugation between each wash, after which 1 mL of sheath fluid was added to the cells and the samples were analyzed by flow cytometry. FIG. 18 shows the average channel number versus the concentration of FITC-RGD peptide added to the cells. The average channel number (y-axis) is a representation of the fluorescence measured from the FITC-RGD peptide and is directly related to the amount of FITC-RGD peptide bound to the cells. The figure shows that as the amount of FITC-RGD peptide increases, the measured fluorescence appears to level off, i.e., reach a plateau. This indicates that concentrations of FITC-RGD peptide above 300 μM saturate all available cell surface binding sites for RGD. Other experiments (not shown) demonstrate that binding of the FITC-RGD peptide was specific to cell receptors capable of binding the RGD peptide.

[0189] Example 10: Demonstration of biological function of RGD-alginate The aim of the experiments was to investigate the biological functionality of RGD-alginate, in particular its binding to cells.

[0190] C2C 12 A dose-response type experiment was set up in which mouse myoblasts (ATCC CRL-1772) were seeded in a 3D cell culture system. Cells were immobilized in the 3D cell culture system using alginate and peptide-linked alginate (PRONOVA UP LVG and NOVATACH RGD) to a final alginate concentration of 0.5%. Cells were exposed to sodium alginate with no alginate peptide, with 0.012 μmol of peptide-linked alginate, or with 0.0012 μmol of peptide-linked alginate. Changes in cell number over time were determined by trypsinization of the cells and counting using a phase contrast microscope and a hemocytometer. These data are shown in Figure 19. Each data point is the average of three individual disks (N=3). Error bars represent standard error.

[0191] C2C 12 Mouse myoblasts are considered anchorage-dependent, i.e., cells need to be attached to a substrate in order to proliferate. Integrins are cell receptors responsible for cell adhesion, and the RGD sequence is the most common peptide motif responsible for cell adhesion to the extracellular matrix (ECM). The RGD peptide sequence is found within many matrix proteins, including fibronectin, fibrinogen, vitronectin, osteopontin, and several other adhesive extracellular matrix proteins. Without the interaction between the integrin receptor and the ECM substrate, cells will not proliferate. This is especially evident when cells are cultured in three-dimensional cell culture systems that do not provide ECM or adhesive proteins. Therefore, the increase in cell proliferation was used as a measure of RGD-alginate binding to cells that showed little or no increase in proliferation when cultured in vitro. All samples containing RGD-alginate showed a measurable increase in cell number by day 14, and the results appeared dose-dependent. Therefore, it can be concluded that RGD-alginate interacts with receptors on cells for cell adhesion and provides a signal for cell adhesion that leads to stimulation of cell proliferation when cells are grown in three-dimensional culture.

Claims

1. 1. An alginate gel comprising: an alginate comprising at least one peptide having a peptide sequence for interacting with a receptor of a cell affected by a proliferative disease; Ba 2+ , Sr 2+ , Ca 2+ , Cu 2+ , Zn 2+ and combinations thereof; and Actinium-225, Actinium-228, Astatine-211, Barium-140, Bismuth-210, Bismuth-211, Bismuth-212, Bismuth-213, Calcium-45, Calcium-47, Copper-64, Francium-221, Gallium-67, Holmium-166, Indium-111, Iridium-192, Iron-59, Lead-211, Lead-212, Lead-214, Lutetium-177, Osmium-191, Osmium-193, Palladium-103, Platinum-197, Radium-223, Radium-224, Radium-225, Rhenium-186, Rhenium-188, Samarium-1 at least one radionuclide cation selected from the group consisting of silver-111, silver-85, strontium-89, tellurium-129, tellurium-132, terbium-160, terbium-161, thallium-201, thallium-206, thallium-210, thorium-227, thorium-231, thorium-234, tin-113, tungsten-185, tungsten-187, vanadium-48, ytterbium-169, yttrium-88, yttrium-90, yttrium-91, zirconium-95, and combinations thereof; Including, the alginate chelates the divalent cation and the at least one radionuclide cation; Alginate gel.

2. 2. The alginate gel of claim 1, wherein the peptide sequence is selected from the group comprising an integrin-binding peptide sequence, an LDL-binding peptide sequence, an MMP-2-binding peptide sequence, an IL13R2a-binding peptide sequence, a VDAC1-binding peptide sequence, an NBD-binding peptide sequence, a cMYC-binding peptide sequence, a CXCR4-binding peptide sequence, an MDGI-binding peptide sequence, and combinations thereof.

3. 3. The alginate gel of claim 1 or 2, wherein the peptide is selected from the group: RGD, TFFYGGSRGKRNNFKTEEY, MCMPCFTTDHQMARKCDDCCGGKGRGKCYGPQCLCR, ACGEMGWGWVRCGGSLCW, SWTWEKKLETAVNLAWTAGNSNKWTWK, TALDWSWLQTE, WPGSGNELKRAFAALRDQI, RACRFFC, ACGLSGLGVA, and RPKPQQFFGLM.

4. 4. An alginate gel according to any one of claims 1 to 3, wherein the peptide sequence is arginine-glycine-aspartic acid.

5. 5. An alginate gel according to any one of claims 1 to 4, wherein the gel is in the form of particles.

6. 6. An alginate gel according to any one of claims 1 to 5, wherein the at least one radionuclide cation is located less than 100 μm below the surface of the alginate gel, preferably less than 50 μm below the surface of the alginate gel, more preferably less than 10 μm below the surface of the alginate gel.

7. 1. A method for providing at least one alginate gel particle comprising an alginate comprising at least one peptide having a peptide sequence for interacting with a receptor of a cell affected by a proliferative disease and at least one radionuclide cation, the method comprising: iv) providing a solution of alginate, said alginate comprising at least one peptide having a peptide sequence for interacting with a receptor of cells affected by a proliferative disease; v) adding the solution from step i) dropwise to an aqueous solution containing divalent cations to form at least one alginate gel particle, wherein the divalent cations are Ca 2+ , Sr 2+ , and Ba 2+ and vi) contacting the alginate gel particles of step ii) with a solution containing at least one radionuclide cation; A method comprising:

8. A composition comprising an alginate gel according to any one of claims 1 to 6 together with at least one pharma- ceutically acceptable carrier, diluent and / or excipient.

9. A kit comprising: In a first container, at least one peptide having a peptide sequence for interacting with a receptor of a cell affected by a proliferative disease; Ba 2+ , Sr 2+ , Ca 2+ , Cu 2+ , Zn 2+ and at least one divalent cation selected from the group consisting of Alginate, including an alginate gel comprising Optionally, with a suitable solvent Including, In a second container, at least one radionuclide cation; With a suitable solvent Including the kit.

10. A kit comprising: In a first container, - a water-soluble alginate, a water-soluble alginate comprising at least one peptide having a peptide sequence for interacting with a receptor of a cell affected by a proliferative disease; - Water, - Optionally with another suitable solvent Including, In a second container, - Water-insoluble particles, said particles being composed of alginate and Ba 2+ , Sr 2+ , Ca 2+ , Cu 2+ , Zn 2+ and combinations thereof; and - Water and Including, In a third vessel, at least one radionuclide cation, - with a suitable solvent Including the kit.

11. A gel according to any one of claims 1 to 6 or a composition according to claim 8 for use as a medicament.

12. A gel according to any one of claims 1 to 6 or a composition according to claim 8 for use in the treatment of a proliferative disease.

13. 13. The gel of any one of claims 1 to 6 or the composition of claim 8, for the use according to claim 11 or claim 12, wherein the proliferative disease is cancer.

14. A gel according to any one of claims 1 to 6 or a composition according to claim 8, for the use according to claim 12 or claim 13, wherein the proliferative disease is a hyperplastic disease or a neoplastic disease.

15. 14. The gel of any one of claims 1 to 6 or the composition of claim 8 for the use according to claim 13, wherein the gel or composition is administered to a cavity of a subject from which cancerous tissue has been removed.

Citation Information

Patent Citations

  • Localized chemotherapy and radiotherapy using in situ hydrogels

    JP2004528278A

  • Hydrogels containing low molecular weight alginate and biostructures made therefrom

    JP2009543892A

  • Pharmaceutical preparations

    JP2014509636A